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1. RATIONALE AND GOAL OF THE STUDY 
 
 
Down syndrome (DS) is a genetic condition due to triplication of human chromosome 21. Cognitive 
disability, that is already present in infants with DS and worsens with age, is the most invalidating 
feature of DS. The trisomic brain is characteristically small starting from early developmental 
stages and produces fewer neurons than the normal brain, suggesting that neurogenesis impairment 
may be a determinant of cognitive disability.  
Dendritic pathology is a consistent feature and represents a possible substrate for mental retardation 
in different conditions. In DS, the pathogenesis of dendritic abnormalities is distinctive and appears 
to correlate to some extent with the cognitive profile. In children and adults with DS, there is a 
marked reduction in dendritic branching and spine density (see(18)). Mouse models that mimic 
human pathologies as closely as possible are becoming invaluable tools because they can be 
exploited to identify the mechanisms underpinning a given pathology and to examine the outcome 
of targeted therapies. The Ts65Dn mouse is a widely used model of DS because it recapitulates 
numerous features of the human condition. Similarly to individuals with DS, the granule cells of 
dentate gyrus and CA3 pyramidal neurons of Ts65Dn mice have less branched and less spinous 
dendrites. Moreover, in the hippocampal field CA3 of Ts65Dn mice the frequency of miniature 
EPSCs is reduced, indicating an overall impoverishment of afferent synaptic input from the dentate 
gyrus, which is in agreement with the reduced number of granule neurons in these trisomic mice.  
Though defective neurogenesis most likely represents a crucial determinant of mental retardation, 
dendritic abnormalities with consequent connectivity alterations are likely to be equally 
important actors in the neurological phenotype of DS.  
DS has long been associated with a loss of serotonin (5-HT) in postmortem brains and there is 
evidence for a reduction in 5-HT levels and dysregulation of the 5-HT1A receptor in the fetal DS 
brain. It is well established that lack of serotonin during early stages of brain development impairs 
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neurogenesis and dendritogenesis. Consequently, in view of the role played by 5-HT in 
neurogenesis and dendritic maturation, dysregulation of this transmitter system may contribute to 
alterations in neurogenesis as well as dendritic pathology in DS. Fluoxetine is a selective serotonin 
reuptake inhibitor that increases serotonin bioavailabilty in the brain. Previous evidence showed 
that administration of fluoxetine during early phases of brain development fully restored 
neurogenesis of granule cell precursors in the dentate gyrus and total number of granule cells and 
that this effect was accompanied by recovery of hippocampus-dependent memory performance 
(28).  
Restoration of neurogenesis in the trisomic brain is an essential but not sufficient prerequisite for 
the rescue of brain functions. It is equally important that neurons are endowed with a well-
developed dendritic arbor, a property that is fundamental for the establishment of proper synaptic 
connections. Several lines of evidence show that fluoxetine has a positive impact on dendritic 
maturation in the normal brain, which is in line with the key effects of serotonin on dendritic 
development and suggests that this drug may improve the typical dendritic pathology that 
characterizes trisomic neurons. Thus, the rescue of cognitive functions observed in trisomic mice 
neonatally treated with fluoxetine may to be underpinned by an improvement/restoration of 
dendritic development that accompanies restoration of neurogenesis. 
Since currently there is no evidence that the defective dendritic development of individuals with DS 
can be pharmacologically rescued, the overall goal of this project was to establish whether 
treatment with fluoxetine restores dendritic pathology and connectivity in addition to 
neurogenesis in the Ts65Dn mouse model of DS.  
The fact that in the DS brain neurons are morphologically normal at birth, but the number of 
dendrites and spines decreases steadily in postnatal life compared to the normal brain, suggests that 
the early postnatal period may represent a critical time window in which an attempt may be made to 
improve dendritic architecture. Thus, to establish whether it is possible to improve dendritic 
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maturation and synaptic function in DS, we treated animals with fluoxetine during the first phases 
of postnatal life. We focused on the effect of pharmacotherapy on the dendritic pattern in the 
hippocampal dentate gyrus and on the functional synaptic connectivity between the dentate gyrus 
and CA3, two hippocampal regions essential for long-term declarative memory. 
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2. INTRODUCTION 
 
2.1 DOWN SYNDROME 
 
Down syndrome (DS) is a genetic pathology due to the triplication of human chromosome 21. Its 
most severe aspect is the mental disability linked to the pathology.  
Trisomy of chromosome 21 can be total or partial, and in most cases DS is not familial. The extra 
chromosome 21 copy usually arises during the formation of the parental germ cell when two 21 
chromosomes stick together in one cell, instead of moving apart and taking a place individually in 
separate cells. This is called non-disjunction. Non-disjunction is more likely in mothers (88%), 
especially older ones, than in fathers (9%), because all of a mother’s eggs are present in an 
immature form before her birth. In contrast, new sperms are continually being produced by fathers 
across their reproductive lifespan. The small remainder of cases of DS are familial ones and reflect 
either traslocation of an extra piece of the long arm of 21 to another chromosome or mosaicism 
(135). 
 
2.1.1 Etiology 
 
Genomic aneuploidy, defined as an abnormal number of copies of a genomic region, is a common 
cause of human genetic disorders.  
Classically, the term aneuploidy was restricted to the presence of supernumerary copies of whole 
chromosomes (trisomy), or absence of chromosomes (monosomy), but now we can extend this 
definition to include deletions or duplications of subchromosomal regions. Trisomy 21 is a model of 
all human disorders that are the result of supernumerary copies of a genomic region (11). In DS, the 
extra copy of genes presents on HSA21 (134) is caused by three types of genetic rearrangements: (i) 
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the presence of a third whole 21st chromosome, (ii) Robertsonian translocation of chromosome 21, 
(iii) mosaicism. 
Full/free trisomy 21(Ts21). This is the most common cause of DS, caused by the presence of a 
third whole 21st chromosome, which is usually of maternal origin. This kind of trisomy is caused by 
a chromosomal non-disjunction: if an egg or a sperm with two 21st chromosomes instead of one 
merges with a normal mate, the fertilized egg has three 21st chromosomes. The net result is that the 
total number of chromosomes in every somatic cell is 47 instead of the normal 46 (71). 
Robertsonian translocation. Robertsonian traslocation is a special type of genetic rearrangements 
where the smaller arms of chromosome break away and the larger arms become fused to those of 
one of a different chromosome pair.  This is the second type of cause in DS, much less prevalent 
than full Ts21, leading to attachment of chromosome 21 to chromosome 14, 21, or 22. So, while the 
number of chromosomes remains normal, there is a triplication of the 21st chromosome material. 
This abnormality may be carried by both parents and can increase the probability of DS in offspring 
(71). 
Mosaicism. This is the third and very rare cause of DS. It is caused by an error in mitotic cell 
division soon after conception (71). Because of this, people with mosaic DS have two cell lines: one 
with the normal number of chromosomes, and one with an extra number 21. This can occur in one 
of two ways: a non-disjunction event during early embryogenesis in a normal embryo or a DS 
embryo undergoes non-disjunction and some of the cells revert to a normal chromosomal 
arrangement.  
 
2.1.2 Epidemiology 
 
DS occurs in 1 every 700–800 live births and epidemiologic data give an estimated incidence of 
more than 200000 cases per year worldwide (44), data that lead to an estimation of 5-6 million of 
case in the world.  
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The birth prevalence of DS increases with maternal age from about 1 in 1500 under age 25 to about 
1 in 100 at age 40 (Fig. 1). 
Over 5700 cases of DS were registered with the UK National Down Syndrome Cytogenetic 
Register from 1989 to 1993 and, of these, 95% were regular trisomy 21 and 1% were mosaic. The 
remaining 4% were due to chromosomal translocations (almost all Robertsonian) (see (127)). 
In the last decades, the number of DS pregnancies has increased, probably due to the old age of 
mothers (94). According to a study published on “American Journal of Public Health” (101), two 
factors which could affect the incidence of DS individuals live birth, through the accessibility to 
prenatal testing (maternal serum screening, nuchal translucency screening, amniocentesis and 
chorionic villus biopsy), are geographic origin and mother occupation.  
 
Figure 1 - Graph (American Family Physician, 2000)  shows links between maternal age and percent chance for Down 
syndrome. 
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The data reveal that socioeconomic differences in use of prenatal testing have created disparities in 
the live-birth prevalence of DS.  
Life expectancy of DS individuals is generally shorter than that of the normal population and varies 
with the severity of the phenotype. However, at least in occident,  in the last years the life 
expectancy of people affected by DS is increased, thanks the care of life, from forties to sixties. 
 
2.1.3 The Human Chromosome 21 (HSA21) 
 
Chromosome 21 is the smallest human chromosome representing about 1.5 percent of the total 
DNA (Fig. 2). Since the discovery in 1959 that DS occurs when there are three copies of 
chromosome 21, about twenty disease loci have been mapped to its long arm (87). 
The short arm of chromosome 21, 21p, is largely made up of ribosomal RNA genes and other repeat 
sequences that are probably involved in other chromosomal abnormalities.  
The long arm, 21q, instead, was estimated to be around 38Mb and approximately 3% of its 
sequence encodes for proteins of different functional categories like transcription factors, regulators 
and modulators; proteases and protease inhibitors; ubiquitin pathway; interferons and immune 
response; kinases; RNA processing; adhesion molecules; channels; receptors; and energy 
metabolism (180). 
There are rich- and poor- genes regions on 21q, which is correlated with the G+C content (87): the 
distal one third of 21q is the most gene-rich while the proximal two thirds are uniformly AT-rich 
(74). But the total number of genes (protein-coding and non coding RNAs) on the long arm has not 
been conclusively determined. 
Currently, about 500 genes and gene models exist on HSA21q and an additional 4 have been 
assigned to HSA21p. Of these, we have information about the function of about 145 (134). An 
additional, unexpected finding is that the actual fraction of chromosome 21 that is transcribed into 
RNA might be an order of magnitude higher than the fraction occupied by gene coding sequences 
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(158). This could lead to additional unidentified genes, RNA transcripts without protein-coding 
capacity, alternative RNA isoforms or “illegitimate” non functional transcription.  
HSA21 is a chromosome with a low content of G-negative bands (that is light band of a 
chromosome after treatment with GIEMSA dye), and thanks the literature, we know that genomic 
regions with G-negative bands are rich of structural genes. The distal half of the HSA21q (21q22) is 
the major G-negative region of the chromosome, and for this reason the band has been associated 
with the syndrome (173) and with development of cognitive disabilities (see(44)). This region of 
~5.4 Mb, between the carbonyl reductase (CBR) and transcriptional regulator ets-related gene 
(ERG), was called “Down Syndrome Critical Region” (DSCR), in turn divided into several “critical 
region”, two of which are called DSCR1 and DSCR2. 
There are two hypotheses to explain the pathogenesis of Down syndrome caused by the genetic 
overdosage. The first one is called “gene dosage effect hypothesis”: it holds that the phenotype is a 
direct result of cumulative effect of the imbalance of the individual gene located on the triplicated 
chromosome or chromosomal region (148). Because of the triplication of a particular subset of 
genes, this is responsible for particular pathological traits associated with trisomy 21. The second 
hypothesis called “amplified developmental instability hypothesis” in contrast claims the imbalance 
of the hundreds of genes on HSA21 determines a non specific disturbance of genomic regulation 
and expression. This global disruption of the correct balance of gene expression in development 
pathways alters the normal developmental homeostasis and determines most manifestation of DS. 
The discussion about validity of one of the two hypotheses is still open. Moreover, the two different 
hypotheses could coexist. Indeed, a recent study provided evidence that trisomy for the DSCR is 
necessary but not sufficient for the brain phenotypes observed in trisomic mice (132), and that 
individual genes on HSA21 act in concert to enhance or ameliorate the deleterious effects of the 
extra copies of genes. 
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2.1.4 The most studied triplicated genes 
 
Among the over-expressed genes of the HSA21, pursuant to Roizen et al. (158), the principal of 
them involved in brain DS phenotype are SIM2, DYRK1A, DSCAM, APP, S100B, SOD1. They 
possibly affect normal brain development and could provoke neuronal loss and Alzheimer’s like 
pathology, when they are in trisomic condition. 
SIM2. Single-minded homolog 2. SIM2 is a basic helix loop helix transcription factor involved in 
normal neuronal development. SIM2 can heterodimerize with aryl hydrocarbon receptor nuclear 
translocator (ARNT) and translocate to the nucleus to transcriptionally regulate gene expression 
(41). His over expression could directly or indirectly induce the neuroanatomic and neurochemical 
abnormalities that often occur in DS (209). 
DYRK1A. Dual-specific tyrosine-(Y)-phosphorylation regulated kinase 1A. DYRK1A is a proline-
directed serine/threonine kinase, which phosphorylates several transcription factors, including 
calcineurin, CREB, NFAT, Synj1, GSK3B, dynamin and FKHR (133). It seems to play a 
significant role during brain development by regulating neurogenesis and neuronal differentiation 
(59). It is considered a strong candidate gene for learning defects in DS. Moreover it contributes to 
AD-like neuropathological features in DS by modulating the formation of intracellular Tau 
inclusions and the production of β-amyloid (133).  
DSCAM. Down syndrome cell adhesion molecule. It is an adhesion protein, mainly expressed in the 
brain, which has conserved functions in developing nervous system across invertebrates and 
vertebrates, including axon guidance, axonal and dendritic branching and targeting, and synapse 
maturation (50). In DSCAM deficient mice, retinal ganglion cells have defects in neuronal spacing 
and dendritic harborization patterns, exhibiting neuronal self-avoidance phenotypes (145). 
APP. Amyloid beta (A4) precursor protein. APP is a trans-membrane protein expressed mainly in 
the synapses of neurons. It participates at synapses formation (143) and neural plasticity (190). APP 
can be processed by the secretases, a family of proteases that include three isoforms: α, β, γ. In turn 
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activity of β and γ secretases bring to the formation of Aβ-42 fragment, a fibrillar peptide which can 
form amyloid plaques. Amyloid plaques are molecular markers of Alzheimer’s disease, but they are 
also present in adult DS individuals. 
S100β. S100 calcium binding protein beta. S100β is a protein produced and released by astroglial 
cells, with particularly high levels during development and aging. In some cases, S100β is trophic 
and promotes differentiation, growth, recovery, and survival of neurons, otherwise it can be toxic 
and lead to cell loss and apoptosis (26). The overexpression of S100β in DS promotes β-amyloid 
plaque formation and progression.  
 
 
Figure 2 - Rachidi and Lopes, 2008, European Journal of Paediatric Neurology - The human chromosome 21 (HSA21). 
The principal genes located on HSA21, the regions 21p (short arm) and 21q (long arm) and their sub-regions, including 
the Down syndrome critical region (DSCR) are represented. 
 
SOD1. Superoxide dismutase 1. This enzyme attaches (binds) to molecules of copper and zinc to 
break down toxic, charged oxygen molecules called superoxide radicals. Superoxide radicals can 
damage cells if too many accumulate within cells. SOD1 converts them in hydrogen peroxide, a 
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much less reactive molecule than superoxide. Superoxide radicals are byoproducts of normal cell 
processes, particularly energy-producing reactions, and must be broken down regularly. In DS 
brains, SOD1 is known to be 50% over-expressed and so hydrogen peroxide is over-produced. 
 
2.1.5 Genes expression profiling in Down Syndrome 
 
Trisomy 21 was the first discovery of a genetic substrate for intellectual disability. Understanding 
the link between the genes carried by chromosome 21 and brain and cognitive disorders stands as a 
challenge for public health (161). To this purpose, gene expression studies have crucial importance 
(147). Analysis of gene transcription provides two kinds of information to understand mental 
retardation pathogenesis in DS. On one hand, these studies allowed identification of genes 
specifically expressed in the brain and, on the other hand, to select them as candidate genes for 
cognitive impairment ((149); (150); (52); (155)). Nowadays, transcriptome studies are evidencing a 
complex transcriptional environment characterized by transcriptional variability of a given gene in 
the different tissues and in the different individuals that complexes the interpretation of the 
overexpression analyses in DS and evaluation of their effects in phenotype determination. The 
results of these works showed different transcriptional changes that could be grouped in three 
classes. The majority of trisomic genes showed transcript levels increased of about 1.5-fold in 
human trisomic tissues ((68) ; (119)). Other HSA21 trisomic genes showed different transcriptional 
changes being overexpressed at different ratios than 1.5 or, for a few of them, a decreased 
expression was found (147). These studies are leading to the identification of potential targets in the 
altered pathways involved in cognitive disability pathogenesis that may be potentially corrected, in 
the perspective of new therapeutic approaches. 
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2.1.6 Phenotype features of DS individuals  
 
Individuals with DS may have some or all of the following physical characteristics: microgenia 
(abnormally small chin), oblique eye fissures with epicanthic (epicanthus: a skin fold of the upper 
eyelid) skin folds on the inner corner of the eyes (formerly known as a mongoloid fold), muscle 
hypotonia (poor muscle tone), a flat nasal bridge, a protruding tongue (due to small oral cavity, and 
an enlarged tongue near the tonsils) or macroglossia, a short neck (127). Although Down’s 
syndrome is usually linked to intellectual disability, the morbidity from other associated congenital 
abnormalities is considerable. Overall, about one in five liveborn children with DS die before the 
age of 5 years, and about two in five survivors have major health problems in addition to 
intellectual disability in early childhood. (90). 
Congenital heart defects. About half of children with DS are born with congenital heart disease. 
The most frequent lesions are atrioventricular septal defect (45% of newborns with DS) and 
ventricular septal defect (35%); isolated secundum atrial septal defects (8%), isolated persistent 
patent ductus arteriosus (7%), isolated tetralogy of Fallot (4%), and other lesions (1%) can also 
arise. Assessment of all newborns with DS with an echocardiogram is the standard recommendation 
(American Academy of Pediatrics Committee on Genetics. 
• Atrioventricular septal defects (AVSDs). Of all the heart defects, AVSDs are the most 
serious and the only ones, which have an adverse impact on survival. AVSDs are a grave 
heart malformation with particular clinical features. In the normal formation of the heart the 
endocardial cushions grow toward each other and leave openings between the atria and the 
ventricles. The mitral and tricuspid valves form in the openings. The AVSDs are caused by 
the formation of a single valve structure with a septal defect above and below it. Depending 
on the location of this valve structure it can also present as an inlet ventricular septal defect 
(resulting in blood flow only between the ventricles) or an ostium primum atrial septal 
defect (leaving only a hole between the atria) (see(127)). AVSDs are genetically linked to 
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HSA21 and are about 420 times more common in those affected with DS than in the general 
population (see (127)). 
• Ventricular septal disease (VSD). VSD is a defect characterized by a hole between the top 
chambers (receiving chambers or atria) which provoke a backwash from the right hearth 
side (pulmonary) to the left (arterial). The holes can be located in the middle of the central 
heart wall (most common), in the top septum (sinus venosus defects) or in the lower part of 
septum (partial atrioventricular septum disease).  
Other rare congenital hearth problems are: patent ductus arteriosus, tetralogy of Fallot, atrial septal 
defects, defects due the pulmonary hypertension. 
Gastrointestinal defects. The second most common malformations in DS individuals are those of 
the gastrointestinal tract. The principal defects are Hirschsprung’s disease (HD), duodenal atresia 
and tracheo-esophageal fistula (see (127)). 
• Hirschsprung’s disease. HD is a relatively rare condition that hits approximately 2% of 
children with DS. It involves a long segment of lower part of the large bowel wall, in which 
there is a loss of nerve cells. This encourages chronic constipation, poor weight gain, 
vomiting and swollen abdomen. There is a form of pathology in which only a short part of 
bowel participates and the symptoms are less severe.  
In addition to the hearth and gastrointestinal deficits, DS individuals could present congenital 
problems like urinary tract malformations (6%), limb defects (9%) and congenital cataract (1%). 
 
2.1.7 Other medical problems associated with DS 
 
There are several serious medical problems associated with DS and some of these are leukaemia, 
epilepsy, hypertension, thyroid disorders and Alzheimer’s disease (AD). 
Leukaemia. DS increases the risk of developing acute megakaryoblastic Leukaemia (AMKL) and 
acute limphoblastic leukaemia (ALL) in comparison with the normal people. Hayes and colleagues 
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reported in their study that 1.65% of the DS children developed leukaemia (see (127)). Usually DS 
patients develop leukaemia before 4 years of age and probably this is due to the trisomy of HSA21, 
which perturbs hematopoiesis, making megakaryocyte-erythroid progenitors susceptible to the 
effects of GATA1 (transcription factor) (205). 
Thyroid disorders. Hypothyroidism develops in one third of patients with DS before the 
age of 25 years.  Because symptoms of hypothyroidism might be mistaken for symptoms related 
to the natural course of DS, it is important to monitor annually for thyroid function (98) in view of 
the fact that neuro-endocrine changes, occurring with aging, have been demonstrated to play a main 
role, not only in homeostasis but also in the occurrence and/or in the progression of metabolic, 
functional and cognitive alterations (66). 
Epilepsy. In a study reported by Noble J, about 15% of DS patients (16-18 years old) were affected 
by epilepsy. The frequency of this disorder is related to the age of the patients, probably because 
epilepsy is a clinical sign of dementia. 
Alzheimer’s disease. A connection between Alzheimer’s disease (AD) and DS has long been 
suspected and in 1987 a gene that codes for a protein (amyloid precursor protein), subsequently 
shown to be involved in the pathogenesis of AD, was located on chromosome 21 (see (127)). By the 
age of 40, 50-70% of DS patients develop dementia. Trisomy of APP is likely to make a significant 
contribution to the greatly increased risk of early-onset AD (205). HSA21 genes other than APP 
may also contribute to the early onset of AD in people with DS. DYRK1A, for example, can 
phosphorylate tau at a key priming site that permits its hyperphosphorylation, followed by 
depolimerization of actin microfilaments, dendritic hypotrophy and neurofibrillary tangles 
formation, Aβ-42 fragment and tau actions affect several brain regions in DS, including prefrontal 
cortex, hippocampus, basal ganglia, thalamus, hypothalamus and midbrain (207). 
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2.1.8 Neurological defects  
 
The most salient feature present in all cases of DS, even in the early infancy (147), is mental 
retardation and it is the most invalidating pathological aspect. Mental retardation is evident as lower 
verbal and mental performance in the mild-to-moderate range, with an IQ varying from 50 to 70 for 
mild disability and from 40 to 50 for moderate disability.  
Generally, individuals with DS have normal performance in simple tasks like associative learning, 
but they have difficulties with spatial memory, and long- and short-term memory performance.  
Most indications suggest that the impairment is not spread across all learning and memory systems 
equally, but instead selectively impacts only some systems (see (126)), like verbal short-term 
memory and explicit long-term memory, with poor information encoding, impaired retrieval 
abilities and attention deficits (see (18)). Usually, for the rest, children with DS have normal 
learning ability for tasks requiring implicit memory, like visual–spatial short-term memory and 
implicit long-term memory, which are relatively preserved. In general, infants with DS show 
relatively normal abilities in learning and memory (see (126)), but in childhood specific deficits in 
verbal short-term memory become apparent (longer period of phonological errors, comprehension, 
cognition); in adolescence, the specific deficits in verbal short-term memory continue, and specific 
working memory deficits become evident (40). DS children perform worse than normal children on 
explicit memory tasks, while they show normal learning ability for tasks requiring implicit memory 
processing. To understand better this point, we have to explain the two types of memory: while 
explicit memory deals with intentional conscious learning and requires information coding and a 
high degree of attention, implicit memory is sustained by automatic processes requiring low 
attention. All these defects are probably due to the impaired brain structure typical of DS: the 
medial temporal lobe, and particularly the hippocampus, as well as parts of the cerebellum, are 
included in this category, but there are also strong evidences about an implication of the prefrontal 
cortex. Patients with DS also show a higher incidence of febrile and non febrile seizures than non-
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DS individuals. Seizures occur in a bimodal distribution in DS, with 40% of individuals first 
developing seizures before 1 year of age and another 40% having an onset in their thirties or later 
(144).  
 
Figure 3 - Elola et al., 2011, Commentary in Disease Model & Mechanism - Syntenic regions of 
MMU17/MMU16/MMU10 and HSA21 (A) and their location on the modified chromosomes of DS mouse models (B) 
 
Boys tend to have an earlier age onset, regardless of seizure type, although this may reflect the 
general male predominance in the infantile spasm group aged less than 1 year at onset. The 
prevalence of epilepsy increases with age and reaches 46% in those over 50. The mechanisms 
underlying the increased seizure susceptibility in DS have not yet been completely elucidated. 
Seizures in infancy have been linked to inherent structural brain  abnormalities, such as fewer 
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inhibitory neurons, abnormal cortical lamination, persistent fetal dendritic morphology, and 
underdeveloped synaptic profiles (100). 
Motor and non motor corticocerebellar and cerebellar-limbic circuits that are involved in attention, 
executive control, language learning, working memory and emotion, might contribute to DS 
cognitive phenotypes. Additionally, cerebellar hypoplasia in DS and motor dysfunction may have 
an important role in the development of learning skills. Impairment in perceptual-motor coupling 
seems to be associated with difficulties in regulating temporal aspects of actions: this problem could 
also affects visuospatial abilities of patients with Down syndrome (192). 
 
2.2 MOUSE DS MODELS: TOOLS FOR THE UNDERSTANDING OF DS PATHOLOGY 
AND THERAPY DESIGN 
 
To overcome the difficulties related to the study of the dosage-sensitive genes underlying DS in 
human subjects, several mouse models  have been developed. 
At the genomic level, the long arm of Hsa21 is approximately 33.7 Mb in length and contains about 
430 protein-coding genes of which 293 have a homolog in the mouse genome. 
These genes are divided in three syntenic regions localized in three different mouse chromosomes: 
Mmu16 (about 23,4 Mb in length with 115 orthologous genes), Mmu17 (1,1 Mb in length with 24 
orthologous genes) and Mmu10 (2.3 Mb in length with 47 orthologous genes) (18). In these three 
syntenic regions, relative order and orientation of the genes are preserved between the two species.  
Mouse models that mimic human pathologies as closely as possible are becoming invaluable tools 
because they can be exploited to identify the mechanisms underpinning a given pathology and to 
examine the outcome of targeted therapies.  
In Fig. 3 are summarized the syntenic region between HSA21 and chromosomes of DS mouse 
models. 
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2.2.1 Model with triplication of  the whole Mmu16 
 
The first mouse model of trisomy 21, generated by spontaneous Robertsonian translocations of 
Mmu16  by Gropp et al (78), is labeled Ts16 and is trisomic for the whole chromosome 16 
(MMU16). Although it is a potential animal model for human trisomy 21, due to the substantial 
homology between the long arm of the human chromosome 21 and the distal portion of mouse 
chromosome 16 ((63) ; (107) ; (153)), its relevance is limited due to its embryonic lethality, given 
that MMU16 also contains hundred of genes located on  HSA3, 8, 16. In order to overcome the 
viability problems associated with murine Ts16, three segmental Ts16 mouse lines have been 
generated: Ts65Dn, TsCje and MsTs65 mice, with Ts65Dn mice showing most similarities to the 
DS phenotype. 
 
2.2.2 Segmental trisomic mice  
 
The best studied model is that of a partial (segmental) trisomy 16, named Ts65Dn (Fig. 4) and was 
created by Davisson et al. in 1990 (54), who provoked a Robertsonian translocation with 
experimental exposure to radiation. The Ts65Dn strains carries an extra chromosome that has a 
region of Mmu16 translocated onto a short segment of Mmu17, and is thus trisomic for ~104 genes 
on Mmu16 that are orthologous to Hsa21 genes. However, it should be noted that it also has three 
copies of 19 genes on Mmu17 that are not orthologues of genes on Hsa21, and thus some 
phenotypes in this strain might not be related to human DS (see (108)). 
Unlike Ts16 mice, Ts65Dn mice live until adulthood and show many clinical phenotypes similar to 
those seen in DS patients.  
The phenotypic abnormalities in the Ts65Dn mouse model are: reduced birth weight, postnatal 
developmental delay, muscular trembling and male sterility, skeletal malformation corresponding to 
the cranio-facial dysmorphogenesis in DS (72). Also brain abnormalities have been found: reduced 
cerebellar volume and neuronal density in the dentate gyrus, reduced thickness of the internal 
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granule and molecular layers and reduced granule cell numbers compared to euploid mice (106). 
Both APP mRNA and APP protein from cerebral cortex are elevated at embryonic day 15 (E15): 
2,5 and 2 fold respectively. Moreover in the Ts65Dn mouse there is an abnormal cholinergic 
function and degeneration of cholinergic basal forebrain neurons. These characteristics are also 
found in DS individuals and are considered the initial signs of the onset of Alzheimer’s disease 
(72). 
Adult Ts65Dn mice exhibit hyperactivity under certain experimental condition, impairment of 
memory and learning. Two studies have shown that long-term potentiation (LTP) and depression 
(LTD), electrophysiological correlates for learning and memory, are abnormal in young adult 
Ts65Dn mice. It has been demonstrated that pyramidal cells of the CA1 subfield from Ts65Dn mice 
have a reduced LTP and an enhanced LTD compared to control animals.  
 
Figure 4 - http://www.jax.org/cyto/mice.html#HHSN275201000006 - The Ts65Dn mouse model. A: Example of a 
Ts65Dn and a control mouse. B: The Ts65Dn mouse model shows segmental trisomy for a distal region of chromosome 
16, a region that shows perfectly conserved linkage with human chromosome 21. C: Fluorescent in situ hybridization 
(FISH) in the Ts65Dn mouse. 
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The fact that there is a significant reduction in the number of neurons in the granule cell layer of the 
dentate gyrus in Ts65Dn (93), may lead to a concomitant decrease in the number of synaptic sites 
available in the dentate gyrus for receiving information through the perforant path. In adult Ts65Dn 
mice, neocortical pyramidal neurons have shorter and less branched dendrites with significantly 
reduced spine numbers as compared to controls. Moreover, synaptic structures of trisomic mice are 
less responsive to stimuli. Cerebellar granule neuron precursors have been isolated and cultured in 
vitro to demonstrate the reduced proliferation in response to mitogenic factors. This aspect may 
affect any trisomic cell and may represent the primary cause of reduced body size, developmental 
defects and premature aging of DS individuals. 
The Ts1Cje mouse model, created by Sago et al, has a duplication of a shorter region of  Mmu16, 
encompassing ~81 genes (from Sod1 to Znf295) with orthologues on Hsa21. Ts1Cje mice show 
reduced cerebellar volume and abnormalities in craniofacial development similarly to Ts65Dn mice, 
but generally less severe. 
The Ms1Ts65 mouse model has a partial trisomy that starts from APP to SOD1 and includes about 
33 genes, the region of difference between Ts65Dn and TsCje. This allows comparisons among the 
trisomies and permits to assess the contributions of the phenotype of Ts65Dn mice of genes 
proximal to App up to Sod1 regarding the learning and behavioral phenotype (162). These 
segmental trisomic mice have fewer similarities to DS than do Ts65Dn and Ts1Cje mice. 
A comparison of Ms1Ts65 and Ts65Dn demonstrates that the deficits of Ms1Ts65 mice in the 
Morris water maze are significantly less severe than those of Ts65Dn, as triplication of the region 
from Sod1 to Mx1 plays a major role in the abnormalities of Ts65Dn in the Morris water maze, 
(162). 
In Ms1Ts65 mice, a neurological alteration has been identified at the cerebellar level: the granule 
cell density is moderately reduced , similarly to Ts1Cje, compared to Ts65Dn mice. 
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Olson et al. (130) addressed the hypothesis that the DS critical region (DSCR) contains all the 
major genes involved in generating DS phenotypes. Using chromosomal engineering they generated 
a new mouse, named Ts1Rhr (131), which was trisomic for the Cbr1-Orf9 genetic interval (DSCR) 
including 33 genes. Somehow, the DSCR was not sufficient to induce the cranio-facial defects in 
mice. Similarly, impairment in learning and memory tasks involving the hippocampus found in 
Ts65Dn mice is not reproduced in Ts1Rhr mice, confirming that the DSCR was not sufficient to 
induce the brain phenotype observed in Ts65Dn models. Interestingly, mice combining the deletion 
of the Cbr1-Orf9 region (Ms1Rhr) with the Ts65Dn trisomy achieve normal performance in the 
Morris water maze (132), indicating that the DSCR is not sufficient but contributes to learning and 
memory. 
Additionally, the Ts2Cje mouse has been recently established after a fortuitous translocation of the 
Ts65Dn marker chromosome to chromosome 12 (193). Both Ts65Dn and Ts2Cje mice, carrying the 
same trisomic segment, showed enlargement of the brain ventricles and impaired neurogenesis (95). 
  
2.2.3 Models with triplication of Mmu17 or Mmu10/16/17 
 
Two models have recently been created, Ts1Yah and Ts43H ((136) ; (191)), which are not trisomic 
for Mmu16 genes, but rather for a segmental region of Mmu17. The Ts1Yah mouse, which is 
trisomic for 12 genes in the Mmu17 region, syntenic to the sub-telomeric region of Hsa21, displays 
deficits in novel object recognition, similarly to other DS models. Conversely, it displays enhanced 
learning in the hippocampus-dependent spatial memory, revealing the complexity of the genetic 
code that modulates different aspects of behavior in DS patients. To distinguish between the 
specific effects of dosage-sensitive genes and non specific effects of a large number of arbitrary 
genes, the Ts(1617)43H (Ts43H) mouse, which is trisomic for 30 Mb of proximal Mmu17, was 
created (191). The Ts43H model exhibited spatial learning deficits analogous to those observed in 
Ts65Dn mice. This is in accordance with the hypothesis that the over-expression of a large number 
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of triplicated genes causes a disruption in genetic homeostasis that impairs gene regulation of 
developmental processes (see (18)). 
Recently a new mouse DS model that carries duplications spanning the entire Hsa21 syntenic 
regions on all Mmu10, Mmu16 and Mmu17 mouse chromosomes has been created 
(Dp(10)1Yey/+;Dp(16)1Yey/+;Dp(17)1Yey/+). This mouse mutant exhibits DS-related 
neurological defects, including impaired learning/memory and decreased hippocampal LTP (212), 
very similarly to the Ts65Dn mouse. These results suggest that the critical genes associated with the 
DS brain phenotypes may reside within the Mrpl39–Zfp295 genomic segment of the Mmu16 and 
support the use of the Ts65Dn mouse as the best genetic murine DS model. 
 
2.2.4 Models with insertion of Hsa21 
 
The Tc1 mouse model, created by O’Doherty et al, has a triplication of the entire human Hsa21. 
This model exhibits several key phenotypes of DS like alterations in synaptic plasticity and 
cerebellar neuronal number ((70); (128); (125)).  
However, the random loss of this human chromosomal fragment during mouse development 
resulted in variable levels of mosaicism of the extra chromosome in different tissues, confounding 
the analysis of phenotypic consequences. Four mouse strains were generated with a trisomy for a 
selected short fragment of Hsa21, to produce polytransgenic mice with partial trisomies for the 
DSCR ((179); (178)). Two of the four polytransgenic mice had learning and memory defects, in 
particular the one containing the Dyrk1a gene. 
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2.2.5 Models with triplication of individual genes 
 
Several transgenic mouse models with one orthologous HSA21 gene were created like TgSod1, 
TgApp, TgEts2, TgS100β, TgDyrk1A, TgDSCR1, TgSim2, TgBACE2, TgSynj1 and TgPfk1 in 
order to evaluate the contribution of triplicated individual genes to the mouse phenotype. 
Recent work focused on the role of Dyrk1a triplication in the cognitive deficit of DS, showing that 
transgenic mice (TgDyrk1a) exhibit various but not all learning defects of Ts65Dn mice (6). 
Extracellular hippocampal recordings in these transgenic mice demonstrated altered induction of 
LTP and LTD during the learning and memory process, although the changes in both processes 
were in the opposite direction to that seen in other more complete trisomic mouse models, namely 
Ts65Dn and Ts1Cje ((103) ; (3)). The transgenic mice for App exhibited over-expression of App in 
the neocortex and hippocampal region, mimicking features of DS. These amyloid precursor protein 
transgenic models with Alzheimer disease-like pathology showed dystrophic neuritis associated 
with plaques and mild learning defects. Learning deficits were shown in transgenic mice 
overexpressing synaptojanin 1 (Synj1) (194), but the learning deficits of Ts65Dn mice was more 
severe. All this data are consistent with the general concept that neurological defects in DS and 
genetic models are the result of contributions of multiple genes. 
 
2.2.6 Trisomic mice with removal of triplicated genes 
 
A last group of DS mouse models was obtained by selectively manipulating the dosage of candidate 
genes. These models were obtained by removing one copy of a specific gene from a mouse model 
of DS and used to examine the behavioral outcome ((35); (58); (194); (37)). For instance, when 
Ts65Dn mice are crossed with a knockout of the App gene, thus reducing App to disomy, the 
development of some cellular abnormalities, including degeneration of basal forebrain cholinergic 
neurons (BFCNs), was prevented (35). 
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2.3  NEUROANATOMY OF DS 
 
The DS brain is characterized by numerous structural alterations that start to be present from early 
developmental stages and are retained in adulthood. 
2.3.1 Gross anatomy 
 
HUMANS 
The DS brain is characterized by shape changes that include an anteroposteriorly shorter cerebrum, 
reduced frontal lobes, flattening of occipital poles and narrowing of the superior temporal gyruses 
((167); (206); (198); (152); (139)). Individuals with DS have a typically reduced brain volume. The 
volume is disproportionately small in frontal, temporal and cerebellar regions and relatively 
preserved in the occipital and parietal cortical gray matter (139). The reduced size of the DS brain 
can be traced back to early developmental stages as hypotrophy of the hippocampus, 
parahippocampal gyrus and cerebellum is already present during gestation ((204); (80)). Magnetic 
resonance images of the corpus callosum in adolescents with DS reveal that callosa are decreased in 
widths throughout their rostral fifth, which serves frontal lobe projections. This correlates with the 
hypocellularity and hypofrontality of neocortex in subjects with DS and with their 
neuropsychological profile of frontal lobe dysfunction (197). Atrophy of the corpus callosum has 
been also seen in non-demented adults with DS (188). In addition, DS patients have an area of the 
anterior commissure smaller compared with that of control subjects (184) and a decrease in white 
matter throughout the inferior brainstem (202). The reduced volume of the white matter and fiber 
tracts is consistent with the reduced number of neurons forming the DS brain (see below). Defective 
biochemical composition of myelin and delay in myelin formation ((208); (20); (104)) are likely to 
contribute to decrease the size of the white matter and fiber tracts. 
MOUSE MODELS 
In Ts65Dn mice, brain volume is reduced during the embryonic period, though at birth and at 
further life stages it is similar to that of euploid mice ((37); (5); (92)). The shape of the hemispheres 
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is characterized by an increase in the height of the posterior cerebrum and a reduction in the 
rostrocaudal length and mediolateral width (5). The overall hippocampal volume and the volume of 
the pyramidal layer are not reduced in Ts65Dn mice ((92); (112); (93)), though the granule cell 
layer and hilus have a reduced volume ((28) ; (46) ; (112)). Unlike the cerebrum, the cerebellum of 
Ts65Dn mice has a notably reduced volume (5). In Ts1Cje and Ts2Cje mice at embryonic day 
14.5 brains are smaller when compared with diploid littermates, which is consistent with the 
reduced neurogenesis (95). At one, three and six months of age the ventricles of Ts1Cje and Ts2Cje 
mice are enlarged, but there are no differences in total brain volume, though the brain has a shorter 
anteroposterior length (95). Another study shows that there are no differences in brain weight in 
Ts1Cje mice aged 6-6.5, 7-7.5 and 9-10 months. (22). Likewise, the area of the hippocampus shows 
no difference between Ts1Cje aged 18 months and the euploid counterpart (22). Similarly to 
Ts65Dn mice, Ts1Cje mice have a reduced cerebellar volume (131). Ms1Rhr mice have a 
cerebrum with reduced volume, height, width and length and a cerebellum with reduced volume (5). 
The cerebrum of Ts1Rhr mice (aged four months) shows a few differences in linear distances vs. 
controls. These include a reduced rostrocaudal and mediolateral lenght of the anterior portion of the 
cerebrum but an increased rostrocaudal length of the posterior portion of the cerebrum (5). While at 
4 months of age Ts1Rhr mice have a reduced volume of the cerebrum and cerebellum, at 7.5 
months they have a brain weight and volume of the posterior hippocampus that are larger than 
euploid mice (21).  
 
2.3.2 Cytoarchitecture, cell density, cell number 
 
HUMANS 
In the DS brain cell density appears normal in early gestation, but there are fewer neurons than 
normal in late gestation (after weeks 19-23), and this paucity continues throughout early life ((199); 
(75); (80)). In fetuses with DS, total neuron number is reduced in the hippocampal dentate gyrus 
 
 
 
26 
 
(DG), hippocampus and parahippocampal gyrus (80) and the cellular layers of the cerebellum are 
characterized by prominent hypocellularity and reduced thickness (81). Morphometric studies in DS 
cases from birth show fewer neurons, lower neuronal densities and cortical dysgenesis (206). 
Children and adults with DS retain a reduced granule cell density in the cerebellum (19) and have a 
greatly reduced number of neurons in the ventral cochlear nucleus, a small nuclear volume, low cell 
packing density (73). Architectonic abnormalities and a significant poverty of granular cells are 
present in the DS brain, particularly in granular fields such as areas 3, 17, and 41 (160). 
Accompanying neuronal alterations are alterations of other cell types: astrocytes, 
oligodendrogliocytes and microglia. Fetuses with DS show an increased astrocyte-neuron ratio in 
all hippocampal structures compared with controls (80). Astrocytic hypertrophy and an increase in 
astrocyte number are present in both the developing and adult DS brain ((77); (123)). Microglia 
appears more prominent in DS and oligodendrogliocyte dysfunction is reflected in delayed 
myelination in pathways of frontal and temporal lobes (20).  
 
MOUSE MODELS 
Development of the neocortex of the Ts16 mouse model is characterized by a transient delay in the 
radial expansion of the cortical wall and a persistent reduction in cortical volume (88). Similarly to 
Ts16 mice, Ts65Dn mice exhibit delayed expansion of the neocortex during the embryonic period, 
though this difference disappears by E18.5 (37). At E18.5, however, despite the cortical growth to 
normal thickness, there is a reduction in cell density. Reduced cell density is present also 
postnatally at P8, specifically in layers IV, V, and VI with no change in the density of layers II–III, 
suggesting a selective deficit in the early born neurons of the deeper cortical layers (37). Similarly 
to the neocortex, the hippocampal wall of Ts65Dn mice has a reduced thickness but this difference, 
which is present from E13.5, persists up to E18.5. The pyramidal cell layer has a very reduced 
thickness and the DG is smaller in size (46). In the hippocampal region of Ts65Dn mice (Fig. 5), 
the granule cell layer of the DG has a reduced number of granule cells across all postnatal life 
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stages ((46); (28); (112); (93)). In contrast, the number of hippocampal pyramidal cells is not 
reduced (112) and in aged Ts65Dn mice the number of cells in hippocampal field CA3 appears to 
be larger vs. controls (93).  
In the hippocampus of Ts65Dn mice the astrocytes exhibit a significant hypertrophy and are more 
numerous, though this difference is not statistically significant (92). The cerebellum of Ts65Dn 
mice has a reduced layer thickness, a reduced granule cells density and number starting from P2 to 
adulthood ((159); (19); (45)). In addition, Purkinje cells density is also reduced (19).  
In Ts1Cje mice aged 18 months, the thickness of the granule cell layer and molecular layer of the 
DG is similar to that of controls (22). Ts1Cje mice show a moderate decrease in cerebellar granule 
cell density and no changes in Purkinje cell density (130). In Ts1Rhr mice aged 7.5 months the 
thickness of the motor cortex has been found to be larger than in euploid mice (21).  
 
 
Figure 5 - Insausti et al., 1998 Neuroscienceletters - 50 µm thick slices of the hippocampus, stained with thionin, of a 
control case (A) and a Ts65Dn case (B). 
 
2.4 CAUSES OF BRAIN HYPOTROPHY IN DS 
 
The widespread hypoplasia of the DS brain is considered to be the main cause of mental retardation. 
Several lines of evidence show that neurogenesis reduction and dendritic hypotrophy are the two 
major determinants of brain hypotrophy in DS: An increase in cell death does not seem to play a 
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role at early life stages, but at more advanced life stages it may contribute to further reduce neuron 
number.  
 
2.4.1 Neurogenesis alterations 
 
The fact that brain and cerebellar volume reduction and cortical hypocellularity are already present 
in children and fetuses with DS ((75); (204); (139)) strongly suggests that defective neuronogenesis 
during critical phases of brain development may be a major determinant of microencephaly. 
Neurons and glial cells destined to form the cortical mantle derive from the embryonic ventricular 
zone (VZ). At advanced stages of embryogenesis the VZ decreases in size and is gradually replaced 
by the subventricular zone (SVZ). The SVZ plays a pivotal role in corticogenesis during the 
embryonic/early postnatal period. At further life stages it produces granule cells that migrate to the 
olfactory bulb (31). Neurons forming the DG derive, initially, from the dentate neuroepithelium, 
which will give rise to the postnatal subgranular zone (SGZ) (8). In rodents, the bulk of DG 
neurogenesis takes place in the early postnatal period and continues at a slower rate into adulthood. 
Neurons forming the cerebellum are mainly formed prenatally, with the exception of the granule 
cells of the inner granule cell layer that are formed both prenatally and in the early postnatal period 
from precursors in the external granular layer (EGL) ((1); (182)). Neurogenesis alterations in the 
VZ, SVZ, SGZ and EGL have been documented in the DS brain.  
HUMANS 
Due to the obvious difficulties in obtained fetal material, very little information is available 
concerning neurogenesis in the fetal DS brain. We recently obtained evidence that in fetuses with 
DS cell proliferation is severely impaired in the DG (most likely due to alteration of the cell cycle), 
in the germinal matrix of the inferior horn of the lateral ventricle and in the germinal zones of the 
hippocampus proper and parahippocampal gyrus ((46); (80)). Quantification of the number of 
mature neurons and astrocytes in the hippocampus and parahippocampal gyrus showed that in all 
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these regions fetuses with DS had proportionally fewer neurons and a larger number of astrocytes 
compared with normal fetuses (80). In trisomic fetuses, we also found a defective neurogenesis in 
the EGL of the cerebellum, and in a region of the fifth lobe that is the remnant of the cerebellar VZ 
(81). This evidence clearly shows proliferation impairment in numerous regions of the fetal DS 
brain. Importantly, these defects are shared by trisomic mice  which validates the use of mouse 
models for DS and renders evidence obtained in mouse model transferable to the human condition. 
 
MOUSE MODELS 
Neurogenesis in the VZ/SVZ. In Ts16 mice the number of precursors of the future somatosensory 
cortex just before neuronogenesis begins, is notably reduced. At each cell cycle during 
neuronogenesis, a smaller proportion of Ts16 progenitors exit the cell cycle and the cell cycle 
duration is longer in Ts16 than in euploid progenitors (89). In the Ts65Dn mouse a reduced 
proliferation has been detected at all examined life stages. Reduced neural precursor proliferation, 
due to elongation of the cell cycle, is already present during embryonic development in the cortical 
and hippocampal VZ, with a reduction in the number of neocortical and hippocampal neurons (37).  
In a subsequent study, Chakrabarty et al. found that in Ts65Dn mice, unlike the cortical and 
hippocampal VZ, the embryonic medial ganglionic eminence (MGE), which is the source of 
inhibitory neurons, undergoes divisions at a normal rate but gives a higher neuronal output, due to a 
large progenitor population (36). Interestingly, there is an imbalance between production of 
excitatory and inhibitory neurons, with an increase in the number of inhibitory neurons. The large 
output from the MGE explains the observation that in the neocortex and hippocampus of neonate 
and young Ts65Dn mice there are fewer excitatory but more inhibitory neurons. This excessive 
production of inhibitory interneurons is due to over-expression of the triplicated genes Olig1 and 
Olig2, as normalization of their expression rescues the Ts65Dn phenotype (36). In Ts65Dn mice, 
the postnatal SVZ of the lateral ventricle, which is the largest neurogenic area of the adult brain, 
presents a remarkably reduced proliferation rate that starts in the perinatal period and continues up 
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to senescence ((189); (28)). A severe neurogenesis reduction has also been documented in the 
embryonic neocortex and VZ and in the SVZ of adult Ts1Cje and Ts2Cje mice (95). In the adult 
Ts1Cje SVZ trisomy does not appear to affect the number of neural stem cells but results in reduced 
numbers of neural progenitors and neuroblasts (91). Analysis of differentiating Ts1Cje neural 
progenitors shows a severe reduction in number of produced neurons and an increase in the number 
of astrocytes (91). 
Neurogenesis in the SGZ. A severe neurogenesis impairment characterizes the DG of the Ts65Dn 
mouse at all examined life stages ((93); (46); (112) ; (28)). The study of the phenotype acquired by 
differentiating neural progenitor shows a reduction in the number of new neurons with an increase 
in the number of astrocytes ((46); (28)). A severe neurogenesis reduction has been documented also 
in the SGZ of adult (3 months) Ts1Cje and Ts2Cje mice (95). 
Neurogenesis in the EGL of the cerebellum. A reduced proliferation of cerebellar granule cell 
precursors in the EGL of Ts65Dn mice has been documented at P0 and P6 (159). This reduction has 
been confirmed in P2 Ts65Dn mice and is due to elongation of the cell cycle (45). Also in the 
cerebellum, an altered differentiation leads to a proportionally smaller percentage of cells that 
acquire a neuronal phenotype and a larger percentage that acquire an astrocytic phenotype (45). 
 
2.4.2 Dendritic hypotrophy 
 
Dendritic pathology is a typical feature of the DS brain and appears to correlate to some extent with 
cognitive profile. 
 
HUMANS 
Dendrites. It has been argued that DS persons start their lives with an apparently normal neuronal 
architecture that progressively degenerates. Thus, normal or even increased branching in the DS 
foetus and newborn contrasts with reduced dendrites and degenerative changes in older children 
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with DS. Becker et al. (1986) showed that in infants with DS younger than 6 months, dendritic 
branching and length in both apical and basilar dendrites were greater than in normal infants. 
During the peak period of dendritic growth and differentiation, quantitative analysis of dendrites in 
layer IIIc pyramidal neurons of prefrontal cortex of the brains of 2.5-month-old infants revealed no 
signiﬁcant differences in dendritic differentiation between euploid and DS cases (195). In contrast, 
the pyramidal neurons of the visual cortex of newborns older than 4 months have shorter basilar 
dendrites (185). These ﬁndings suggest that children with DS begin their lives with morphologically 
normal layer III pyramidal neurons and that pathologic changes in key prefrontal input–output 
neuronal elements occur after 2.5 months of postnatal age. Subsequent to this age, there is a steady 
decrease so that in subjects with DS older than 2 years, these parameters are reduced relative to 
controls especially in apical dendrites. Dendritic hypotrophy is also present in pyramidal neurons of 
the parietal cortex of children with DS (176). The dendritic hypotrophy seen in childhood continues 
into adulthood, with a marked decrease in dendritic branching and dendritic length in elderly adults 
with DS (186). This evidence shows that unlike in normal brains, where accomplishment of 
dendritic maturation is attained in early childhood, in DS brains the dendritic tree begins to be 
atrophic in early infancy without a recovery at subsequent life stages.  
In agreement with the deteriorated dendritic development, various proteins forming neuron 
cytoscheleton or associated with the endoplasmic reticulum are down-regulated in the DS brain. 
These proteins include the microtubule-associated protein MAP2 (129), beta-tubulin and 
neurofilament proteins of medium (NF-M) and high (NF-H) molecular-weight, ((140); (62)); actin-
related protein complex 2/3 (Arp2/3) (200), actin-related protein 3beta (ARP3beta) (175), centractin 
alpha and F-actin capping protein alpha-1, alpha-2 and beta subunits (82), the neuroendocrine-
specific protein C (NSP-C) (102) and moesin, which is involved in plasma membrane-actin 
cytoskeleton cross-linking (113). Moreover, the ratios of beta-tubulin and NFs in relation to beta 
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actin are notably decreased (140). All these changes may be involved in the deteriorated neuritic 
outgrowth and arborization of DS neurons. 
Spines. While in the visual cortex of fetuses with DS spine counts (basilar dendrites) are similar to 
those of control fetuses, newborns and older infants with DS have a decreased number of spines and 
spines exhibit an altered morphology (185). In normal subjects, spine density on the basal dendrites 
of cortical pyramidal neurons increases from neonate to 15 years of age and gradually decrease after 
20 years. In contrast, spine density poorly increases in children and rapidly decreases in adults with 
DS ((183); (186); (187)). A reduced spine density has been found in the apical dendrites of 
pyramidal neurons of the hippocampus and cingulate cortex and in both the apical and basilar 
dendritic arbors of CA1 and CA2-3 pyramidal neurons in patients with DS when compared to age-
matched control ((183); (186); (187)). An additional decrease in spine density occurs in DS patients 
with associated AD, when compared to age-matched controls with no AD ((186); (67)). The 
dendritic spines of the DS brain exhibit, in addition to reduced density, also aberrant morphology. 
Spines are small, have short stalks and are intermingled with unusually long spines starting from 
infancy ((120); (146)). Drebrin A, one of the most abundant neuron-specific F-actin binding 
proteins, regulates dendritic spine morphology, size and density, presumably via regulation of actin 
cytoskeleton remodeling. Consistent with the reduced spine density, drebrin, is manifold decreased 
in brains of fetuses and adults with DS ((174); (199)). Over-expression of drebrin A results in the 
alteration of the normal excitatory-inhibitory ratio in favor of excitation in mature hippocampal 
neurons (96). Considering that drebrin expression is reduced in DS individuals (174), a reduced 
excitatory-inhibitory ratio is expected in DS individuals, which may lead to neuron hypoexcitation. 
It is expected that all these dendritic alterations lead to impairment of synaptic function. The most 
obvious mechanism by which dendritic pathology in general and reductions in dendritic 
arborizations in particular, could lead to neurologic impairment is a decrease in the cortical 
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postsynaptic surface. Dendritic hypotrophy should correlate with a reductions in synaptic density, 
while spine dysgenesis may represent a preferential reduction in excitatory synapses (99).  
 
Figure 6 - Benavides-Piccione et al., 2004, Review in Progress in Neurobiology - Camera lucida drawings of basal 
dendritic arbours of layer III pyramidal neurons from wild type and Ts65Dn mice. Scale bar = 150 µm. 
 
MOUSE MODELS 
 
Dendrites. In Ts65Dn mice aged 10 weeks the pyramidal cells of the neocortex are smaller and 
have fewer and shorter basal dendritic branches than controls (24) (Fig. 6). While in the brain of 
neonate Ts65Dn mice the levels of the dendritic marker MAP2 are significantly increased compared 
to littermate controls (141), in hippocampal extracts of adult (4 months) Ts65Dn mice MAP2 is 
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expressed at levels similar to those of littermate controls, However, in the hippocampal formation of 
middle-aged Ts65Dn mice (9-15 months old) MAP2 undergoes a decrease vs. controls (76), 
suggesting an age-related dendritic deterioration. 
 
Spines. In Ts65Dn mice the basal dendrites of neocortical pyramidal cells exhibit a reduced spine 
density (57). A spine density reduction is also present in the granule cells of the DG, accompanied 
by a reorganization of inhibitory inputs, with a relative decrease in inputs to dendrite shafts and an 
increase in inputs to the necks of spines ((23); (142)). The thorny excrescences of CA3 pyramidal 
neurons (the site of termination of the axons of the granule cells) also exhibit a large decrease in the 
number of thorns (142). In addition to density reduction, spines of Ts65Dn mice exhibit an aberrant 
morphology; spines in the DG, field CA1, motor, somatosensory and entorhinal cortices, and 
medial septum of young (21 days) and adult Ts65Dn mice have a larger volume when compared to 
euploid mice (23). A decrease in spine density, an increase in the size of spine heads, a decrease in 
the length of spine necks and a reorganization of inhibitory inputs also appear in the granule cells of 
Ts1Cje mice, though these changes are less severe than in Ts65Dn mice (22). Likewise, the granule 
cells of Ts2Cje mice have enlarged spines with decreased density (193). Similarly to other mouse 
models, the granule cells of Ts1Rhr mice exhibit a reduced spine density. In contrast, spine density 
is not reduced in dendritic trees of pyramidal neurons in the motor cortex (21). Dendritic spines of 
Ts1Rhr mice show a significant increase in the size of spine heads without changes in the spine 
neck, both in the cortex and DG (21). 
 
2.5 ALTERATIONS OF SYNAPTIC FUNCTION IN THE DS BRAIN AND TRISOMIC 
GENES INVOLVED  
 
The proper neuronal function is related to the machinery involved in the release of 
neurotransmitters, the relative weight of excitatory and inhibitory inputs, the balance among 
different neurotransmitter systems and density and function of the corresponding receptors. The DS 
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brain is characterized by numerous defects at the synaptic levels that span from subtle synaptic 
alterations to patent alterations of various transmitter systems.  
 
2.5.1 Synaptic density, excitatory vs. inhibitory synapses 
 
HUMANS 
To our knowledge, no data are available on synaptic density and relative abundance of 
excitatory/inhibitory synapses in the DS brain.  
MOUSE MODELS 
In the neocortex and hippocampal field CA1 of Ts65Dn mice a reduction in synaptic density has 
been detected as early as P8 (37). The synaptic density and the synapse-to-neuron ratio are reduced 
in the DG and hippocampal fields CA3 and CA1 of adult Ts65Dn mice (106), with a reduced ratio 
that is specific for asymmetric synapses (presumably excitatory), while symmetric synapses 
(presumably inhibitory) are unchanged. In aged Ts65Dn mice the temporal cortex has a lower 
number (30%) of asymmetric synapses while the number of symmetric synapses is not different vs. 
controls (105).The reduced number of excitatory synapses in Ts65Dn mice seems in agreement with 
the reduced levels of excitatory aminoacids found in the parahippocampal gyrus of patients with DS 
(157). The increase in the number of GABAergic interneurons found in the primary somatosensory 
cortex of 4-5 month old Ts65Dn mice (137) suggests that in some brain region excessive inhibition 
may be due to an absolute increase in the number of inhibitory synapses.  
 
2.5.2 Synaptic proteins 
 
HUMANS 
Synapses in DS brain exhibit various alterations in the expression of synaptic proteins. Synapsin I 
(a pre-synaptic protein which binds synaptic vesicles to the cytoskeleton and regulates synaptic 
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vesicle release) is expressed at lower levels in neurospheres from human embryonic tissue ((14)). 
Moreover, in various brain areas of DS individuals there are significantly lower levels of 
synaptophysin (a pre-synaptic vesicle membrane glycoprotein known to mediate vesicle release) 
and SNAP-25 (soluble N-ethylmaleimide-sensitive fusion attachment protein) compared with 
controls ((60); (199)). Since all these protein play a role in the regulation of transmitter release, their 
down regulation may compromise synaptic function. Synaptojanin, a synaptic protein thought to be 
involved in clathrin-mediated synaptic vesicle endocytosis, is mapped on Hsa21q22.2. Consistent 
with Hsa21 triplication, excessive expression of synaptojanin has been demonstrated in the 
cerebrum of individuals with DS from fetus to adult period (12). In addition to changes in the 
expression of synaptic proteins, synapses of individuals with DS show abnormalities in synaptic 
length and contact zones (206).  
 
MOUSE MODELS 
In Ts65Dn neonate brains, the levels of synaptophysin, synapsin, spinophilin (a scaffold protein 
that is involved in spine morphology and density regulation) are similar to those of littermate 
controls (141). In 3 month-old Ts65Dn mice, synapses show relatively few changes outside of those 
expected from gene triplication (e.g., synaptojanin). For example synaptosomes prepared from the 
cerebrum of wild type and Ts65Dn mice exhibit no differences in their content of VGLUT1 or 
VGAT, presynaptic transporters necessary for the vesicular uptake of glutamate and gamma-
aminobutyric acid (GABA), respectively, suggesting that the total number of excitatory and 
inhibitory vesicles is conserved (65). Moreover, there are no differences in the levels of other 
presynaptic proteins, such as synapsin, synaptotagmin (a putative calcium sensor in the presynaptic 
terminal) and synaptophysin (65). In the somatosensory cortex of 4-5 month-old Ts65Dn mice there 
is an increment of synaptophysin vs. euploid littermates (137). In the hippocampus of adult (4 
months) Ts65Dn mice, whereas synapsin, spinophilin and gephyrin are expressed at levels similar 
to those of controls, the expression levels of synaptophysin are significantly decreased (141). The 
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inconsistent results of different studies suggest that the expression of synaptic proteins in trisomic 
mice may differ according to age and brain regions.  
 
2.5.3 Electrophysiology  
 
HUMANS 
In view of the obvious obstacles, there is no electrophysiological evidence of synaptic function in 
individual regions of the DS brain. Electroencephalogram (EEG) recordings, however, can provide 
information on the overall cortical activity. A study of EEG coherence in subjects with DS (from 6 
months to 30 years) shows some coherence differences vs. controls that became more prominent 
with increasing age (169). Da Nobrega at al. (51) showed that though a typical EEG pattern for DS 
could not be established, 20.7% of the examined patients had EEG abnormalities and 31.3% of 
these were epileptic. The high incidence of epilepsy in individuals with DS is difficult to reconcile 
with the over-inhibition found in mouse models for DS (see below). Recent evidence, however, 
shows that GABAB receptor agonists have convulsant properties in rodents (47). Given that an 
enhanced GABAB receptor function occurs in DS patients, similarly to Ts65Dn mice (25), this may 
be one of the mechanisms that contributes to the high incidence of epilepsy in children with DS. 
Devinsky et al. reported a relatively preserved EEG alpha activity in young individuals with DS but 
an abnormal activity in older patients with dementia (56).  
 
MOUSE MODELS 
In Ts65Dn, Ts1Cje, Ts1Rhr and Tc1 mice, while basal synaptic transmission in the DG is normal, 
LTP is impaired as a result of reduced activation of NMDA receptors ((103); (22); (21); (128)). 
After suppression of inhibition with picrotoxin, a GABAA receptor antagonist, NMDA receptor-
mediated currents are normalized and induction of LTP is restored, indicating that an excess of 
GABAA receptor-mediated inhibition underlies impairment of LTP. Ts65Dn mice exhibit increased 
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G-protein-activated inwardly rectifying potassium channel 2 (Girk2), a protein that is encoded by a 
triplicated gene, in various cortical regions and hippocampus (86). In hippocampal neurons, Girk 
channels generate a GABAB receptor-dependent slow inhibitory postsynaptic potential (114). 
Several lines of evidence suggest that an increase in Girk2 gene-dosage may have a functional 
effect on the balance of excitatory and inhibitory neuronal transmission perturbed in DS models 
((177); (36)). An excessive GABAB receptor-mediated inhibition due to Girk2 over-expression (25) 
may contribute to impair the induction of LTP in trisomic mice. In addition, since the formation of 
synapses is activity-dependent, an exaggerated inhibition through the GABAA and GABAB–GIRK 
signaling may contribute to disrupt spine formation. Seizures have never been reported in Ts65Dn 
mice. Based on the convulsant properties of GABAB receptor agonists, Cortez and colleagues 
sought to establish whether these drugs might induce seizures (47). They found that such treatments 
produce clusters of extensor spasms in the Ts65Dn mouse that were associated with burst 
discharges in EEG recordings. Unlike the other mouse models, Ts1Yah mice exhibit enhancement 
of LTP, which is consistent with their better performance in the Morris water maze test (136). 
 
2.5.4 Trisomic genes and dendritic/synaptic alterations 
 
Dyrk1a, has been reported not only to influence neurogenesis but also dendritic development 
((211); (84)). Dyrk1A regulates development of the dendritic trees of neurones and modulates the 
activity of the c-AMP response element-binding protein (CREB), which participates in signal 
transduction pathways involved in synaptic plasticity and neuronal differentiation. Moreover, 
Dyrk1a may modulate dendrite development by regulating vesicle trafficking which is dependent on 
Dynamin1 (84), a GTPase putative substrate of Dyrk1a that plays a fundamental role in neurite 
outgrowth (42). Interestingly, mice with one functional copy of Dyrk1a (Dyrk1a+/− mutants) display 
a brain size 30% smaller than that of wild-type mice, considerably smaller and less branched 
cortical pyramidal cells and behavioral defects (24). In humans, DYRK1A has been proposed to be 
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associated with microcephaly and mental retardation, given its localization to the minimal 
overlapping region observed in patients with partial monosomy 21 ((121); (124)). Transgenic mice 
over-expressing Dyrk1a exhibit altered synaptic plasticity associated to learning and memory 
defects (4). These studies with human and animal models, which are monoallelic or triallelic for 
DYRK1A/Dyrk1a, indicate that this gene is important in neural plasticity and necessary for the 
normal size and development of the brain in a dosage-sensitive way. 
DSCR1 (Down syndrome critical region gene 1), also called myocyte-enriched calcineurin-
interacting protein 1 (MCIP1) or calcipressin 1 (CSP1), acts as a negative regulator of calcineurin-
mediated signaling. Calcineurin, that acts mainly by activation of the NFAT (nuclear factor of 
activated T-cells) transcription factor, plays several important roles in the brain, in particular 
modulates synaptic formation and function and memory development ((170); (118); (214)). Over-
expression of DSCR1 in the brain of individuals with DS (69), and the learning defects in 
Drosophila due to over-expression of the DSCR1 homologue (nebula) (38), suggest that DSCR1, 
through calcineurin-mediated signaling inhibition, may be involved in DS neurological defects. 
Notably, inhibition of calcineurin activity leads to increased NMDAR mean open time and opening 
probability (110), supporting the view that altered excitatory neurotransmission may arise from 
DSCR1 over-expression in the DS brain. Recently, it has been demonstrated that DYRK1A and 
DSCR1, both located in the critical DCR-1 region of human chromosome 21, act synergistically to 
block NFAT dependent transcription, suggesting a cooperation of two trisomic genes in the DS 
developmental phenotypes.  
 
2.6 THERAPEUTIC APPROACHES IN THE DS MOUSE MODEL 
 
The preceding sections showed that the cognitive impairment in individuals with DS is underpinned 
by a constellation of brain defects. Ideally, identification of the mechanisms underlying the 
abnormalities of brain development that characterize DS will provide a rational basis to devise 
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therapies that, by targeting specific cellular pathway/s, may correct the developmental defects of the 
DS brain. Though various laboratories are trying to unravel the causes of brain malfunctioning in 
DS, the molecular mechanisms underlying the DS neurological phenotype remain still obscure. Yet, 
various attempts have done to specifically rescue different facets of brain alterations in DS, by 
exploiting drugs and/or neurobiological factors that are known to have a positive impact on the 
brain of normal individuals. 
Mouse models are the principal tool exploited for therapeutic approaches aimed at finding an 
effective treatment for DS. Historically, the choice of potential therapeutic agents in preclinical 
research involving  mouse models for DS has followed four different strategies: 1) compensation 
for the putatively enhanced function of a trisomic gene product; 2) modulation the molecular target 
of a trisomic gene product; 3) compensation of an observed phenotype; and 4) modulation of a 
molecular target associated with a pathway thought to be perturbed by the overexpression of 
trisomic gene products. A recent review describes the therapeutic approaches attempted so far (48).  
 
Target 
Treatment 
(Mechanism of 
action) 
Assessment Outcome Reference 
Compensation 
for the 
putatively 
enhanced 
function of a 
trisomic gene 
 
Sod1/↑ ROS Vitamin E 
(Antioxidant) 
Water-escape 
radial arm maze 
Rescued Lockrow et al. 
Sod1/↑ ROS Vitamin E 
(Antioxidant) 
Elevated-plus 
maze and Morris 
water maze 
Rescued Shichiri et al. 
App DAPT (γ-
secretase 
inhibitor) 
 
Morris water 
maze 
Rescued Netzer et al. 
Dyrk1a EGCG 
(polyphenol, 
found in large 
concentration in 
Object 
recognition test 
Rescued Guedj et al. 
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green and fairly 
specific 
DYRK1A 
inhibitor activity) 
Dyrk1a EGCG 
(polyphenol, 
found in large 
concentration in 
green and fairly 
specific 
DYRK1A 
inhibitor activity) 
LTP Rescued Xie et al. 
Dyrk1a Harmine 
(selective 
DYRK1A activity 
inhibitor) 
Level of plasma 
homocysteine 
Rescued Noll et al. 
Dyrk1a Harmine 
(selective 
DYRK1A activity 
inhibitor) 
Premature 
neuronal 
differentiation in 
cell culture 
Rescued Mazur-Kolecka 
et al. 
Girk2 (?) / 5-
HT1A / ↓ 
Serotonin Level 
(?) 
Fluoxetine 
(selective 
serotonin 
reuptake 
inhibitor, Girk2-
containing 
channel 
antagonist?) 
Hippocampal 
neurogenesis 
Rescued Clark et al. 
Girk2 (?) / 5-
HT1A / ↓ 
Serotonin Level 
(?) 
Fluoxetine 
(selective 
serotonin 
reuptake 
inhibitor, Girk2-
containing 
channel 
antagonist?) 
Contextual fear 
conditioning 
Rescued Bianchi et al. 
Girk2 (?) / 5-
HT1A / ↓ 
Serotonin Level 
(?) 
Fluoxetine 
(selective 
serotonin 
reuptake 
inhibitor, Girk2-
containing 
channel 
antagonist?) 
Morris water 
maze 
Failed Heinin et al. 
Girk2 (?) / 5-
HT1A / ↓ 
Serotonin 
Fluoxetine 
(selective 
serotonin 
reuptake 
inhibitor, Girk2-
containing 
Granule cells 
morphology 
Rescued Guidi et al. 
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channel 
antagonist?) 
Girk2 (?) Ethosuximide and 
Gabapentin 
(antiepileptic 
drugs with and 
without Girk2-
containing 
channel 
antagonistic 
properties) 
Morris water 
maze, and cued – 
or context – fear 
conditioning 
Failed Vidal et al. 
Modulation the 
molecular target 
of a trisomic 
gene 
 
GABAB receptors 
/ Girk2 
CGP55845 
(GABAB receptor 
antagonist) 
Novel place 
recognition, novel 
object 
recognition, 
contextual fear, 
and LTP 
Rescued Kleschevnikov 
et al. 
Noradrenergic 
receptors / App 
I-DOPS and 
carbidopa 
Contextual fear 
conditioning 
Rescued Salehi et al. 
Brain-derived 
neurotrophic 
factor (BDNF) 
Neurotropin 
(analgesic widely 
used in Japan for 
treatment of 
disorders 
associated with 
chronic pain, and 
show to stimulate 
the expression of 
BDNF)   
Radial-arm water 
maze and BDNF 
expression levels 
Rescued Fukuda et al. 
Reduced 
astrocytic release 
of Activity 
Dependent 
Neuroprotective 
Protein (ADNP) 
and Activity 
Dependent 
Neurotrophic 
Factor (ADNF). 
NAPVSIPQ and 
SALLRSIPA 
(active fragments 
of ADNP and 
ADNF) 
NR2A and NR2B 
Levels 
Rescued Vink et al. 
Reduced 
astrocytic release 
of Activity 
Dependent 
Neuroprotective 
Protein (ADNP) 
and Activity 
NAPVSIPQ and 
SALLRSIPA 
(active fragments 
of ADNP and 
ADNF) 
Motor and 
sensory 
milestones 
Rescued Toso et al. 
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Dependent 
Neurotrophic 
Factor (ADNF). 
Increased 
GABAA receptor-
mediated 
neuronal 
inhibition 
Pictotoxin 
(GABAA receptor 
antagonist) 
LTP Rescued Kleschevnikov 
et al. 
Increased 
GABAA receptor-
mediated 
neuronal 
inhibition 
Pictotoxin 
(GABAA receptor 
antagonist) 
LTP Rescued Costa and 
Grybko 
Increased 
GABAA receptor-
mediated 
neuronal 
inhibition 
PZT (GABAA 
receptor 
antagonist) 
Novel object 
recognition and 
LTP 
Rescued Fernandez et al. 
Increased 
GABAA receptor-
mediated 
neuronal 
inhibition 
PZT (GABAA 
receptor 
antagonist) 
Morris water 
maze 
Rescued Rueda et al. 
Increased 
GABAA receptor-
mediated 
neuronal 
inhibition 
Compound α5IA 
(Inverse Agonist 
of α5-containing 
GABAA 
receptors) 
 
Morris water 
maze and 
Expression of 
IEGs 
Rescued Braudeau et al. 
Increased 
GABAA receptor-
mediated 
neuronal 
inhibition 
Compound α5IA 
(Inverse Agonist 
of α5-containing 
GABAA 
receptors) 
Novel-object 
recognition and 
Morris water 
maze 
Rescued Braudeau et al. 
Modulation of a 
molecular target 
through to be 
involved in a 
pathway 
perturbed by 
trisomic genes 
 
NMDA receptor 
(altered gating 
properties?) 
Memantine 
(NMDA receptor 
antagonist) 
Contextual fear 
conditioning 
Rescued Costa et al. 
NMDA receptor 
(altered gating 
properties?) 
Memantine 
(NMDA receptor 
antagonist) 
LTD Rescued Scott-McKean 
and Costa 
NMDA receptor 
(altered gating 
properties?) 
Memantine 
(NMDA receptor 
antagonist) 
Novel object 
recognition 
Rescued Lockrow et al. 
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NMDA receptor 
(altered gating 
properties?) 
Memantine 
(NMDA receptor 
antagonist) 
Morris water 
maze 
Rescued Rueda et al. 
 
Table 1 - Summary of the preclinical studies in DS. 
 
Table 1 clearly shows that it is possible to pharmacologically improve some of the 
morphofunctional defects of the trisomic brain and related behavior in mouse models of DS. Most 
of these studies have been carried out in adult animals with a certain degree of success. This 
achievement is of obvious relevance because it gives the demonstration that something can be done 
for adults with DS. It must be noted, however, that in spite of a certain degree of plasticity retained 
in adulthood, the overall organization of the brain mainly depends on events taking place during 
embryonic and perinatal life stages. Considering that one of the most severe defects of trisomy is 
early neurogenesis impairment, therapies to improve this defect should be started as soon as 
possible, otherwise the brain will have a permanently reduced asset of neurons. Likewise, the severe 
dendritic pathology due to trisomy should be restored as early as possible, in order to consent the 
establishment of appropriate neuronal connections. 
 
2.7 RESTORATION OF THE SEROTONERGIC SYSTEM:  A TOOL FOR IMPROVING 
BRAIN DEVELOPMENT IN DS?  
 
2.7.1 Serotonergic system in normal brain development 
 
Serotonin named also 5-hydroxytryptamine (5-HT), is a monoamine neurotransmitter initially 
found in the gastrointestinal tract and then, in the central nervous system of humans and animals. 
This was the first evidence that serotonin has a role in the maintenance of normal and abnormal 
brain function. The serotonergic system derives from the Raphe nuclei of the brainstem.  
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Figure 7- Modified from http://dmangus.blogspot.it/2012/06/damsio-on-complexity-of-mind-and.html - Release and 
reuptake of 5-HT. Serotonin activates the 5-HTRs on the post-synaptic cell membrane. It is recycled by SERT in the 
presynaptic terminal. 
 
 
It innervates the entire brain, including the hippocampus, substantia nigra, striatum, nucleus 
accumbens, cerebellum and spinal cord. For this reason 5-HT has several functions in the CNS, 
such as the regulation of mood, appetite, circadian rhythms, learning and memory. The serotonin 
receptors belong to the 5-HT receptors family. They are both inhibitory and excitatory and are able 
to modulate the release of many neurotransmitters, including glutamate, GABA, dopamine, 
noradrenaline and acetylcholine. 5-HT receptors are classified in seven families: six are G protein-
coupled receptors, and one is a ligand-gated ion channel Another important protein which interacts 
with 5-HT is the serotonin transporter (SERT) that mediates the serotonin reuptake from the 
synaptic space to the presynaptic terminal in a sodium-dependent manner, thereby interrupting the 
action of the neurotransmitter (Fig. 7). 
Serotonin can increase cell proliferation in the two major neurogenic regions of the thelencephalon, 
the subventricular zone (SVZ) of the lateral ventricle and subgranular zone (SGZ) of the 
hippocampal dentate gyrus. Following either acute or chronic 5-HT depletion, a significant decrease 
in the number of newborn cells in the SVZ and SGZ has been evidenced (32). Administration of 
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agonists of serotonin receptors increases neurogenesis both in the SVZ and SGZ. Serotonin might 
increase cell proliferation by directly acting on receptors expressed by progenitor cells; this is 
consistent with evidence that serotonin receptor 1A (5-HT1A) might be expressed by neural stem 
cells (16). 
In the developing fetal brain, neurotransmitters like amino acids and monoamines (serotonin, 
noradrenaline and dopamine) appear at a time before they assume their roles as neurotransmitters 
and have an established role in maturation of the central nervous system. All of the monoamine 
neurotransmitter systems are present relatively early, but in particular serotonine is likely present 
the earliest (201). In the human brain, serotonergic neurons are evident by 5 weeks of gestation and 
increase rapidly through the 10th week of gestation. The molecules serotonin, dopamine, γ-
aminobutyric acid and taurine are critical for brain development because they promote the detailed 
wiring within the developing fetal brain. Serotonin appears to influence neurogenesis also in the 
adult brain, since depletion of serotonin decreases neurogenesis in the hippocampal dentate gyrus 
(32). During brain development serotonin plays also a role in dendritic development, including 
overall dendritic length, spine formation and branching in the hippocampus and cortex. In adult 
animals, removal of serotonin cases loss of dendrites, which may be reversed by treatment with 5-
HT1A receptor agonists ((13); (201)). 
 
2.7.2 Serotonergic system in DS 
 
DS has long been associated with a loss of serotonin (5-HT) in postmortem brain (117). Whittle et 
al. (203) provide evidence for a reduction in serotonin, dopamine, γ-aminobutyric acid and taurine 
levels in the fetal DS brain. In vitro studies have demonstrated that decreases in the concentration of 
these compounds result in dysfunctional brain developmental events, such as generation, migration, 
and differentiation of neurons and glial cells (203). The trisomic gene S100β appears to negatively 
regulate the outgrowth of serotonin terminals which may contribute to the reduced serotonin levels 
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in DS (201). Moreover, 5-HT1A receptor peaks earlier in developing DS brains and decreases to 
below normal levels by birth (17). Similarly to individuals with DS, Ts65Dn mice exhibit a reduced 
expression of the 5-HT1A receptor at neonatal life stages (28). The reduced expression of the 5-
HT1A receptor, in conjunction with the reduced 5-HT levels in fetuses and adults with DS (157), 
indicates a generalized impairment of the serotonergic transmission. Thus, in view of the role of 5-
HT in neurogenesis, neuronal differentiation, dendritic development, axon myelination and 
synaptogenesis (201), the impairment of this transmitter system in DS, during the most critical time 
window of brain development, may be a key determinant of neurogenesis and neuron maturation 
impairment. If so, treatments that increase serotonin availability may prove useful in compensating 
for these defects. 
 
2.8 PHARMACOTHERAPY WITH SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS 
 
Selective serotonin re-uptake inhibitors (SSRIs) increase the level of 5-HT in the synaptic cleft 
by inhibiting its reuptake. There is growing interest in antidepressant drugs because it has been 
found that multiple classes of antidepressant drugs, including selective serotonin reuptake 
inhibitors, increase neurogenesis in the DG and SVZ ((116); (172)) and can reverse or prevent the 
decrease in hippocampal volume of depressed subjects (115). This raises the possibility of 
pharmacologically improving neurogenesis with drugs that are usable by humans in order to correct 
brain pathologies characterized by reduced neuron production/neurodegeneration.  
 
2.8.1 Fluoxetine modulates neurogenesis and dendritogenesis 
 
Fluoxetine is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class widely 
used by adults and increasingly prescribed in children and adolescents (30) to treat a wide spectrum 
of mood disorders. It has no patent aversive effects on somatic development ((15); (61)). It was first 
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used more than ten years ago, and soon after its introduction it became the most prescribed agent for 
depression in many countries.  
Fluoxetine was shown to be effective for depression in 6-week long double-blind controlled trials, 
where it also alleviated anxiety and improved sleep. The peculiar pharmacokinetics of fluoxetine 
with its brain levels rising extremely slowly over at least the first 5 weeks of treatment makes it 
unclear whether the 20-mg/day optimal dose established in the short term (6-8 weeks) trials is 
applicable for the longer term supportive treatment.  
Fluoxetine and neurogenesis  
A first study in adult (2-5 months old) Ts65Dn mice examined the effect of chronic treatment (28 
days) with fluoxetine (5 mg/kg). They found that trisomic mice had a reduced neurogenesis in the 
DG and that treatment with fluoxetine restored neurogenesis (43). Since this study did not examine 
the effect of treatment on behavior it was not possible to establish whether the neurogenesis 
increase was followed by an improvement of hippocampus-dependent memory functions.  
More recently, Bianchi et al. (28) treated neonate Ts65Dn mice with fluoxetine for 13 days, from 
P2 to P15. This strategy was adopted because in mice more than 80% of the hippocampal granule 
cells are born in the first two postnatal weeks. Treatment with fluoxetine completely restored 
proliferation in both the DG and SVZ, the source of cortical cells during the prenatal and perinatal 
period. This proliferative effects of fluoxetine in the SGZ and SVZ were not accompanied by a 
higher death rate. Moreover, the short-term effects of fluoxetine on cell proliferation were followed 
by a positive and enduring effect on cell survival, with an expansion of the pool of cycling cells. 
Importantly, in Ts65Dn mice not only did fluoxetine increase cell proliferation and survival but it 
also affected the differentiation program, increasing the percentage of cells that acquired a neuronal 
phenotype, thereby fully restoring neuronogenesis. All this evidence indicates that treatment with 
fluoxetine is able to fully restore neurogenesis in Ts65Dn mice by increasing the number of actively 
dividing cells, increasing their survival rate, and favoring acquisition of a neuronal phenotype. In 
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agreement with this concept, also the number and the density of granule cells were restored by 
fluoxetine (28). Increases in neurogenesis after fluoxetine administration require the activation of 5-
HT1A receptors (166), which is in agreement with evidence that 5-HT1A receptor antagonists 
decrease cell proliferation in the dentate gyrus (151). Thus, the 5-HT1A receptor plays a key role in 
the regulation of neurogenesis. Defective 5-HT1A receptor expression in precursor cells of Ts65Dn 
mice may underlie proliferation impairment: this is supported by the finding that in Ts65Dn mice 
treatment with fluoxetine restored the expression of the 5-HT1A receptor and this effect was 
accompanied by rescue of proliferation. Brain-derived neurotrophic factor (BDNF) plays a key role 
in hippocampal neurogenesis by increasing cell survival and neuronal differentiation (163) and 
chronic treatment with antidepressants increases its expression (115). In Ts65Dn mice fluoxetine 
restored BDNF expression, suggesting that this may be the mechanism whereby treatment increased 
the survival of newborn cells and restored the differentiation program. Consistently with previous 
evidence (164), contextual fear conditioning, a task that is considered to involve in addition to the 
amygdala also hippocampus-dependent memory functions (138), was impaired in trisomic mice. 
After treatment with fluoxetine the performance of trisomic mice became similar to that of euploid 
mice, showing that the neurogenesis increase was functionally effective (28). 
Fluoxetine and dendritic architecture 
In view of the role played by serotonin in neuron maturation, it is likely that serotonin reuptake 
inhibitors, such as fluoxetine, exert their positive effects on the DS brain by improving/restoring 
dendritic maturation and connectivity in addition to increasing neurogenesis. This possibility is 
strengthened by evidence that, in the rat hippocampus, fluoxetine modulates the cytoskeletal 
microtubular systems, which plays a fundamental role in dendritic and axon remodeling (27). In 
addition, treatment with fluoxetine triggers pyramidal dendritic spine synapse formation in rat 
hippocampus (83) and renormalizes dendrite atrophy of hippocampal neurons. Finally, chronic 
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treatment with fluoxetine in normal mice accelerates the maturation of immature granule neurons, 
with an increase in dendritic length (196). 
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3. MATERIALS AND METODS 
 
3.1 Colony 
 
Female Ts65Dn mice carrying a partial trisomy of chromosome 16 (154) were obtained from 
Jackson Laboratories (Bar Harbour, ME, USA) and maintained on the original genetic background 
by mating them with C57BL/6JEi x C3SnHeSnJ (B6EiC3) F1 males. Animals were karyotyped 
using real-time quantitative PCR (RTqPCR) as previously described (111). Genotyping was 
validated with fluorescent in situ hybridization (FISH) (181). 
The day of birth was designed as postnatal day (P) 0. A total of 132 mice were used. The animals’ 
health and comfort were controlled by the veterinary service. The animals had access to water and 
food ad libitum and lived in a room with a 12:12 hour dark/light cycle. Experiments were 
performed in accordance with the Italian and European Community law for the use of experimental 
animals and were approved by Bologna University Bioethical Committee. In this study all efforts 
were made to minimize animal suffering and to keep the number of animals used to a minimum.  
 
3.2 Experimental protocol 
 
Euploid (n = 34) and Ts65Dn (n = 29) mice received a daily subcutaneous injection (at 09:00–10:00 
h) of fluoxetine (Sigma-Aldrich, St. Louis, MO, USA) in 0.9% NaCl solution from P3 to P15 (dose: 
5 mg/kg from P3 to P7; 10 mg/kg from P8 to P15).We chose a maximum 10 mg/kg dose because, 
as a result of the extremely short half-life of fluoxetine in rodents compared with humans, a daily 10 
mg/kg dose is thought to produce a brain concentration of a magnitude similar to that of 20–60 mg 
taken daily by humans ((33); (55)). Age-matched euploid (n = 34) and Ts65Dn (n = 35) mice were 
injected with the vehicle (Fig. 8). Each treatment group had approximately the same composition of 
males and females. On P45, animals were deeply anesthetized with ether and killed. A first group of 
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animals (n = 8 for each experimental condition) was transcardially perfused with ice-cold 
phosphate-buffered saline (PBS) followed by a 4% solution of paraformaldehyde in PBS. Brains 
were stored in the fixative for 24 h, cut along the midline and placed in a 20% sucrose in phosphate 
buffer solution for an additional 24 h.  
 
 
Figure 8 - Outline of the experimental protocol 
 
Hemispheres were frozen and stored at -80°C. The left and right hemispheres were cut with a 
freezing microtome in 30-µm-thick coronal sections that were serially collected in antifreeze 
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solution containing sodium azide. Sections from the right hemisphere were used for doublecortin 
(DCX) immunohistochemistry and polysialylated neural cell adhesion molecule (PSA-NCAM), 
sections from the left hemisphere were used for synaptophysin (SYN) and vesicular glutamate 
transporter 1 (VGLUT1) immunohistochemistry and for Down syndrome cell adhesion molecule 
(DSCAM) immunohistochemistry. 
A second group of animals (n = 6–9 for each experimental condition) was not perfused, the brain 
was quickly removed, cut along the midline, rinsed in PBS and Golgi stained, as described below. 
A third group of animals (n = 10 for each experimental condition) was not perfused, the brain was 
quickly removed, the hippocampal region of each hemisphere was dissected and kept at -80°C. The 
hippocampus of one side was used for either Western blotting (n = 5 for each experimental 
condition) or RT-qPCR analysis (n = 5 for each experimental condition) and the hippocampus of 
the other side was used for analysis of serotonin levels (n = 5 for each experimental condition). Two 
additional groups of untreated animals aged 2 days (four euploid and five Ts65Dn mice) and 15 
days (6 euploid and 5 Ts65Dn mice) were used to examine the expression of the 5-HT1A receptor 
in the hippocampal region. Animals belonging to a fourth group of animals (n = 4–8 for each 
experimental condition) were used for electrophysiological recordings from field CA3. 
 
3.3 Histological procedures 
 
DCX immunohistochemistry. One out of six free-floating sections from the DG was processed for 
DCX immunohistochemistry. Sections were permeabilized with 0.1%Triton X-100 in PBS for 30 
minutes and subsequently endogenous peroxidase activity was inhibited using a methanol/H2O2 
0.3% solution for 30 minutes. Sections were incubated overnight at 4°C with a primary antibody 
anti-DCX (goat polyclonal, Santa Cruz Biotechnology, Santa Cruz, CA, USA) diluted 1:100. 
Sections were then incubated for 1 h at room temperature with a biotinylated anti-goat IgG 
secondary antibody (dilution 1:200, Vector Laboratories Inc., Burlingame, CA, USA) and thereafter 
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incubated for 1 h with VECTASTAIN® ABC kit (Vector Laboratories). Detection was performed 
using DAB kit (Vector Laboratories). 
 
Golgi method. Brains were Golgi stained using the FD Rapid Golgi StainTM Kit (FD 
NeuroTechnologies, Inc., Columbia, MD, USA). Brains were immersed in the impregnation 
solution containing mercuric chloride, potassium dichromate, and potassium chromate, and stored at 
room temperature in darkness for 3 weeks. Hemispheres were cut with a microtome in 90-mm-thick 
coronal sections that were mounted on gelatin-coated slides and were air dried at room temperature 
in the dark for 1 day. After drying, sections were rinsed with distilled water and subsequently 
stained in a developing solution (FD Rapid Golgi Stain Kit). 
 
SYN, VGLUT1 DSCAM immunohistochemistry. Free-floating sections (n = 3–4 per animal) 
from the hippocampal formation were submitted to double fluorescence immunohistochemistry for 
SYN and VGLUT1 or DSCAM immunohistochemistry. For SYN and VGLUT1 
immunohistochemistry, sections were incubated for 48 h at 4°C with mouse monoclonal anti-SYN 
(SY38) antibody (Millipore Bioscience Research Reagents, Merck Millipore, Billerica, MA, USA) 
and rabbit polyclonal anti-VGLUT1 (Abcam, Cambridge, UK, Europe) antibody both diluted 
1:1000. Sections were then incubated overnight at 4°C with a DyLight-conjugated goat anti-mouse 
IgG (Thermo Scientific, Rockford, IL, USA) and a RRX-conjugated donkey anti-rabbit IgG 
(Jackson Laboratory, Bar Harbor, ME, USA) both diluted 1:100. For DSCAM 
immunohistochemistry, sections were incubated overnight at 4°C with a primary antibody anti-
DSCAM (generous gift from Dr Maria Luz Montesinos) (9) diluted 1:50. Sections were then 
incubated for 1 h at room temperature with a CY3-conjugated donkey anti-rabbit (Jackson 
Laboratory) diluted 1:200. 
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PSA-NCAM immunohistochemistry. Free-floating sections (n =3–4 per animal) were 
permeabilized with 0.1% Triton X-100 in PBS, blocked for 1 h in 1.5% Goat Serum in 0.1% Triton 
X-100 and PBS, incubated overnight at 4°C with an anti-Polysialic Acid-NCAM mouse monoclonal 
antibody (Chemicon), diluted 1:100. Sections were then incubated for 2 h with a peroxidase-
conjugated AffiniPure goat anti-Mouse IgM secondary antibody (Jackson ImmunoResearch), 
diluted 1:200, reacted with diaminobenzidine and rinsed in water, mounted on glass slides and 
dehydrated with a gradient of alcohols, cleared and cover slipped. 
 
3.4 Western blotting 
 
Total proteins from the hippocampal formation were obtained by homogenization and protein 
concentration was estimated by the Lowry method. Proteins (20 µg) were subjected to 
electrophoresis on a 4%–20% Mini-PROTEAN® TGX™ Precast Gel (Bio-Rad) and transferred to 
a Hybond ECL nitrocellulose membrane (Amersham Life Science, Arlington Heights, IL, USA). 
The following primary antibodies were used: anti-SYN (1:1000, Millipore Bioscience Research 
Reagents); anti-DSCAM (1:500, a gift from Dr Maria Luz Montesinos); anti-VGLUT1 (1:1000, 
Abcam) and anti- GAPDH (1:5000, Sigma, St Louis, MO, USA) antibodies. Densitometric analysis 
of digitized images was performed with Scion Image software (Scion Corporation, Frederick,MD, 
USA), and intensity for each band was normalized to the intensity of the corresponding GAPDH 
band. 
 
3.5 High-performance liquid chromatography (HPLC) 
 
The left hippocampus was homogenized with ultrasonic cell disruptor in Acapulco buffer solution 
(methanol-acetonitrile-50 mM phosphate buffer, pH 2.8, 15:8:77, containing 200 mg/L of sodium 
dodecylsulphate). One volume of homogenate was diluted in 3 vol. of water and 50-mL portions of 
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clear supernatants were directly injected into a HPLC system, as described by Grossi et al (79) 
Protein levels in the sampled tissue were evaluated by Lowry method. The measured amounts of 5-
HT and 5-hydroxyindoleacetic acid (HIAA) were expressed as pg/ng protein. 
 
3.6 Real-time reverse transcriptase quantitative PCR (RT-qPCR) 
 
Total RNA was extracted from the hippocampus of the right hemisphere with TriReagent (Sigma-
Aldrich) according to the manufacturer’s instructions. Complementary DNA (cDNA) synthesis was 
achieved with 1.0 mg of total RNA using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA, 
USA) according to the manufacturer’s instructions. The used primer sequences are as follows: (i) 
brain-derived neurotrophic factor (BDNF) (NM_007540.4), forward 59- 
GTGACAGTATTAGCGAGTG-39 and reverse 59- GCCTTCCTTCGTGTAACC-39; (ii) 5-
hydroxytryptamine (serotonin) receptor 1A (5-HT1A) (NM_ 008308), forward 5′-
ACAGGGCGGTGGGGACTC-3′ and reverse 5′-CAAGCAGGCGGGGACATAGG-3′; (iii) solute 
carrier family 6 (neurotransmitter transporter serotonin alias SERT) (NM_010484.2), forward 5′-
GATCCCTGCTCACACTGACATC-3′ and reverse 5′- CCATAGAACCAAGACACGACGAC-3′; 
(iiii) glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (NM_008084.2), forward 5′-
GAACATCATCCCTGCATCCA-3′ and reverse 5′-CCAGTGAGCTTCCCGTTCA-3′.  
Real-time PCR was performed using a SYBR Premix Ex Taq kit (Takara, Shiga, Japan) according 
to the manufacturer’s instructions in an iQ5 real-time PCR detection system (Bio-Rad). 
Fluorescence was determined at the last step of every cycle. Real-time PCR assay was done under 
the following universal conditions: 2 minutes at 50°C, 10 minutes at 95°C, 50 cycles of 
denaturation at 95°C for 15 s, and annealing/extension at 60°C for 1 minute. Quantifications were 
normalized using endogenous control GAPDH. Relative quantification was performed using the Δ 
ΔCt method. 
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3.7 Patch-clamp experiments: preparation of slices 
 
Mice were anaesthetised by inhalation of isoflurane (Merial Italia, Milan, Italy) and decapitated. 
The brain was quickly extracted under hypothermic conditions and submerged in an icecold 
artificial cerebro-spinal fluid (ACSF) composed of (in mmol l-1): 125 NaCl, 3 KCl, 24 NaHCO3, 
1.25 KH2PO4, 1.2 MgSO4, 2 CaCl2, 10 D-glucose (pH 7.4 by saturation with 95% O2, 5% CO2). 
Two coronal cuts were made, in order to remove the anterior half and the occipital pole of the brain, 
and the piece thus obtained was laid on the posterior section plane. The tissue was blocked on the 
stage of a Microslicer DTK-1000 vibratome (Dosaka, Kyoto, Japan) using cyanoacrilate glue. 
During the sectioning procedure the tissue was submerged in an ice-cold (∼ 1°C) cutting solution 
containing (in mmol l-1): 130 K-gluconate, 15 KCl, 20 N-2-hydroxyethyl piperazine-N-2-
ethanesulphonic acid (HEPES), 0.2 EGTA, 11 D-glucose (pH 7.4 with KOH). 
The use of this high-K+ solution was found to improve neuron viability (Ste´phane Dieudonne´, 
unpublished results). 350 micron-thick sagittal sections across the dorsal hippocampus were cut, 
then rinsed in ACSF and transferred to an incubation chamber filled with the same solution 
(continuously bubbled with 95% O2, 5% CO2). The slices were kept submerged in the incubation 
chamber at room temperature for at least one hour before the recording was started. 
 
3.8 Patch-clamp experiments: voltage-clamp recordings, drugs, and data analysis 
 
Whole-cell, patch-clamp recordings from CA3 pyramidal neurons were carried out on acute slices 
of the dorsal hippocampus obtained as described above (Figure 9A). The experimental set-up 
employed and the basic procedures followed were the same as described by Castelli et al (34). 
Briefly, cells were visualized by means of an upright microscope (Axioskop 2 FS; Zeiss, 
Oberkochen, FRG) equipped with a 660 water-immersion objective lens, differential contrast optics, 
and a near-infrared charge-coupled device (CCD) camera. Slices were perfused with ACSF 
(continuously bubbled with 95% O2, 5% CO2) at a rate of about 1.5 ml/min. Patch pipettes were 
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fabricated from thick-wall borosilicate glass capillaries (CEI GC 150–7.5; Harvard Apparatus, 
Edenbridge, UK) by means of a Sutter P-87 horizontal puller (Sutter Instruments, Novato, CA, 
USA).  
 
Figure 9 - A: Schematic drawing of a section across the hippocampal formation showing the major intrinsic 
connections. Patch clamp recording (rec) of miniature synaptic potentials were carried out from pyramidal neurons of 
field CA3. The area occupied by the mossy fiber terminals in the stratum lucidum of field CA3 is indicated in gray. B: 
Mossy fiber circuitry in CA3. Mossy fibers establish excitatory synapses (+) with pyramidal neurons and inhibitory 
interneurons in the stratum lucidum. Inhibitory interneurons establish inhibitory synapses (-) with the pyramidal 
neurons. Abbreviations: CA1-3, hippocampal fields; DG, dentate gyrus; IN, inhibitory interneuron; MF, mossy fivers; 
PN, pyramidal neuron; PP, perforant pathway; PYR, pyramidal layer; SCH, Shaffer collaterals; SL, stratum lucidum. 
 
The pipette solution contained (in mmol/l): 150 CsF, 4 CsCl, 2 MgCl2, 10 N-2-hydroxyethyl 
piperazine-N-2-ethanesulphonic acid (HEPES), 10 ethylene glycol-bis (b-aminoethylether) 
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N,N,N9,N9-tetraacetic acid (EGTA), 2 adenosine 59-triphosphate (ATP)-Na2, 0.2 guanosine 59-
triphosphate (GTP)-Na, 2.5 lidocaine N-ethyl bromide (QX-314) (pH adjusted to 7.2 with CsOH). 
The patch pipettes had a resistance of 3–5 MΩ when filled with the above solution. Tight seals (<5 
GΩ) and the whole cell configuration were obtained by suction according to the standard technique 
(see ((34)).  
Voltage-clamp recordings of Na+ currents were performed at room temperature (21–22 °C) by 
means of an Axopatch 200B patch-clamp amplifier (Axon Instruments, Foster City, CA, USA). 
Series resistance (Rs) was evaluated on line by canceling the whole-cell capacitive transients 
evoked by -5-mV voltage square pulses with the amplifier built-in compensation section, and 
reading out the corresponding values. Rs was normally 5–12 MΩ and always <20 MΩ, and was 
compensated by ∼90%. Current signals were acquired in gap-free modality with a personal 
computer interfaced to a Digidata 1322A interface (Axon Instr.) using the Clampex program of the 
pClamp 8.2 software package (Axon Instr.). Current signals were low-pass filtered at 5 kHz and 
digitized at 20 kHz. All drugs applied were preliminarily dissolved in concentrated aliquots and 
stored at -20°C, then re-dissolved to the final concentrations in ACSF and delivered to the recorded 
cells via the general perfusion. Tetrodotoxin (TTx) was purchased from Alomone Labs. (Jerusalem, 
Israel), 1(S),9(R)-(2)-bicuculline methiodide and QX-314 were purchased from Sigma-Aldrich 
S.r.l.(Milan,Italy), and 2,3-dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]-quinoxaline-7-sulfonamide 
(NBQX), D-(-)-2-amino-5-phosphonopentanoic acid (APV), and (2S,2’R,3’R)-2-(2’,3’-
dicarboxycyclopropyl) glycine (DCG-IV) from Tocris (Bristol, UK). mEPSCs and mIPSCs, 
recorded under the conditions specified in the Results, were off-line detected using an automated 
threshold routine in the LabView environment written and kindly provided by Dr. G. Biella 
(University of Pavia). All detected events were also visually inspected one-by-one for confirmation 
or rejection. 
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3.9 Measurements 
 
Neuron sampling. Series of sections across the whole rostro-caudal extent of the DG were used for 
reconstruction of DCX-positive and Golgi stained neurons. DCX-positive neurons were sampled in 
the inner part of the granule cell layer, close to the subgranular zone (Figure 10). The Golgi method 
casually impregnates a few neurons among a given population and allows one to sample relatively 
isolated neurons. Golgi-stained neurons were sampled from the outer part of the granule cell layer 
(Fig. 10). The total number of DCX-positive sampled neurons was 29–52 per animal and the 
number of sampled Golgi-stained neurons was 10–16 per animal. Only well-impregnated neurons 
were chosen for the histological analysis. The drawings were made on coded slides so that the 
drawer was not aware of the animal’s treatment. 
 
 
Figure 10 - New granule cells are generated from progenitor cells residing in the subgranular zone (SGZ). The oldest 
granule cells (black) occupy the outer portion of the granule cell layer (GR) and later born cells are added according to 
an outside-inside pattern. The photomicrographs show a mature Golgi-stained cell (black arrow) in the outermost 
portion of the GR and a young doublecortin (DCX)-positive granule cell (blue arrow) in the innermost portion of the 
GR. The dendrites of the mature granule cells occupy the whole molecular layer (MOL) while those of the young 
granule cells reach only the innermost portion of this layer. 
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Measurement of the dendritic tree. The following systems were used: (i) light microscope (Leitz, 
Hexagon Metrology GmbH, Wetzlar, Germany, Europe) equipped with a motorized stage and focus 
control system; (ii) color digital video camera attached to the microscope; and (iii) Image Pro Plus 
(Media Cybernetics, Silver Spring, MD 20910, USA) with the StagePro module for controlling the 
motorized stage in the x, y and z directions, as primary software. Dendritic trees of DCX-positive 
and Golgi-stained granule cells of the DG were traced with a dedicated software, custom-designed 
for dendritic reconstruction (Immagini Computer, Milan, Italy), interfaced with Image Pro Plus. The 
dendritic tree was traced live, at a final magnification of 500x, by focusing into the depth of the 
section.  
 
Figure 11 - Computerized reconstruction of granule cell dendrites. Dendrites were traced in a centrifugal direction. 
Numbers indicate the different dendritic orders (marked by the software with different colors). 
 
The operator starts with branches emerging from the cell soma and after having drawn the first 
parent branch goes on with all daughter branches of the next order in a centrifugal direction (Fig. 
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11). At the end of tracing, the program reconstructs the number and length of individual branches, 
the mean length of branches of each order, and total dendritic length. 
 
Spine density. In Golgi-stained sections, spines of granule cells were counted using a 100x oil 
immersion objective lens. Spine density values were obtained from dendritic segments in the inner 
and outer half of the molecular layer. For each neuron, three segments were analyzed in the outer 
and inner half of the molecular layer, respectively. For each animal, spines were counted in the 
same neuron population used for dendritic reconstruction. The length of each dendritic segment was 
determined by tracing the dendritic shaft and the number of spines was counted manually. The 
linear spine density was calculated by dividing the total number of spines by the length of the 
dendritic segment. Spine density was expressed as number of spines per 100 µm dendrite. 
The axons of the granule cells project to field CA3 and make synaptic contacts with the thorny 
excrescences located on the proximal part of the dendritic shaft of CA3 pyramidal neurons. The 
thorny excrescences are protrusions on the dendritic shaft and are formed by 2–5 spine-like 
structures. Spines of CA3 pyramidal neurons were counted using a 100x oil immersion objective 
lens. The length of the shaft covered by spinous excrescences was determined and the number of 
individual spines of the thorny excrescences was counted manually. The linear spine density was 
calculated by dividing the total number of spines by the length of the dendritic segment. Spine 
density of CA3 pyramidal neurons was expressed as number of spines per 20 µm dendrite. 
 
DSCAM levels in the molecular layer of the DG. Intensity of DSCAM IR in the molecular layer 
of the DG was determined by optical densitometry. Fluorescence images were captured using a 
Nikon Eclipse E600 microscope (see above). The optical density (OD) was evaluated in a box of 
1600 µm2 randomly placed at six different sites in the molecular layer of the upper blade of the DG. 
The OD of the sampled regions was corrected by the background. 
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Connectivity in the hippocampal formation. To study innervation of granule cell dendrites and of 
apical dendrites of CA3 pyramidal neurons, intensity of SYN immunoreactivity (IR) was 
determined in the molecular layer of the DG and in the stratum lucidum of field CA3, by optical 
densitometry of immunohistochemically stained sections (n = 3–4 per animal). In the stratum 
lucidum of field CA3 the IR of VGLUT1 was also evaluated. Fluorescence images were captured 
using a Nikon Eclipse E600 microscope equipped with a Nikon Digital Camera DXM1200 ATI 
System (Nikon Instruments Inc., Melville, NY, USA). Densitometric analysis of SYN was carried 
out using the Nis-Elements Software 3.21.03 (Nikon, Melville, NY, USA). A box of 490 µm2 was 
used and placed in the inner, middle and outer third of the molecular layer of the upper blade of the 
DG and in the stratum lucidum of CA3. Six measurements were taken for each region. For each 
image, the intensity threshold was estimated by analyzing the distribution of pixel intensities in the 
image areas that did not contain IR. This value was then subtracted to calculate IR of each sampled 
area. 
 
Glutamatergic innervation of the hippocampal formation. Dual-channel confocal microscopy 
was used to study co-localization of SYN with VGLUT1 in the molecular layer of the DG and in 
the stratum lucidum of field CA3. Sections were scanned with Nikon Ti-E fluorescence microscope 
coupled with A1R confocal system (Nikon). The lasers were: Multi-Ar (457/488/514) with exciting 
wavelengths for DyLight 488 and 561 diode-pumped solid state laser (DPSS) with exciting 
wavelengths for RRX. The conditions for co-localization analysis were: the objective was an oil 
immersion x60 objective [numerical aperture (NA) 1.4]; laser power was kept low in order to avoid 
photobleaching; the zoom factor was 6; and software Nis-Elements AR 3.2 was used and image size 
was 512 x 512 pixels. For each image, the intensity thresholds were estimated by analyzing the 
distribution of pixel intensities in the image areas that did not contain IR. This value, the 
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background threshold, was then subtracted, and the green-red co-localization coefficient was 
calculated. 
 
Density of synaptophysin immunoreactive puncta in the stratum lucidum of field CA3. From 
the same sections indicated above, we evaluated the density of individual puncta exhibiting SYN 
immunoreactivity in the stratum lucidum (image size; 512x512 pixels; three images per section). 
 
Thickness of the mossy fiber bundle. The axons of the granule cells, the mossy fibers, can be 
visualized with PSA-NCAM immunohistochemistry ((171); (165)). In each sampled section, the 
area of the region occupied by the mossy fibers in field CA3 was first measured by tracing its 
contour. The length of this area was then obtained by tracing a line at its border with the pyramidal 
layer of field CA3. The thickness of the mossy fiber system increases, progressing from the hilus of 
the dentate gyrus toward field CA2. To estimate the mean thickness of the system over field CA3, 
we divided the area occupied by mossy fibers by its length. Measurements of individual sections 
were averaged in each animal to obtain the mean thickness of the mossy fiber terminal field. 
 
Statistical analysis. Results are presented as the mean ± standard deviation (SD) of the mean. Data 
from single animals were the unity of analysis. Statistical testing was performed with analysis of 
variance (ANOVA) followed by post hoc comparisons with Duncan’s test or Bonferroni test. A 
probability level of P < 0.05 was considered to be statistically significant. 
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4. RESULTS 
 
4.1 Effect of fluoxetine on the dendritic tree of newborn granule cells in euploid and Ts65Dn 
mice 
 
Granule cells are derived from precursors in the subgranular zone of the DG that migrate from the 
place of birth to the overlying granule cell layer. In rats and mice, only 20% of the granule cells are 
born before birth and most of the remaining 80% are born in the first two postnatal weeks, with a 
peak at postnatal day 7 ((7); (10); (168)). At variance with neurons forming the neocortex, granule 
cells migrate according to an “outside-inside” pattern. Namely, the oldest neurons populate the 
outer part of the granule cell layer and the youngest populate the inner part (see Fig. 10). 
DCX is a microtubule-associated phosphoprotein selectively located in the periphery of the soma 
with a pattern that overlaps microtubule distribution (49). DCX is expressed widely in migrating 
neuroblasts and differentiating neurons. Dendritic morphology of newborn granule cells can be 
analyzed with immunohistochemistry for DCX, taking advantage of the expression of this protein in 
the cytoplasm of immature neurons during the period of neurite elongation (from 1 to 4 weeks after 
neuron birth). In view of the time course of DCX expression in the granule cells, DCX-positive 
cells present in P45 animals are, necessarily, cells born after P15, that is, in the month that followed 
treatment. To establish the effect of genotype and treatment on dendritic development of granule 
cells born after cessation of treatment, we examined the dendritic morphology of DCX-positive 
cells. 
In agreement with the morphogenesis of the granule cell layer, DCX-positive cells were located in 
the innermost portion of the layer, close to the hilus (Fig. 9). In view of their young age, these cells 
exhibited a dendritic tree with an immature pattern, characterized by a relatively low number of 
short processes that reached the inner but not the outer part of the molecular layer (Fig. 12A–D). 
Fig. 12E shows that DCX-positive cells exhibited a range of morphologies, with branches of low 
orders only (Fig. 12E, neuron “a”), branches of low and intermediate order (Fig. 12E, neuron “b”) 
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and branches of low, intermediate and high order (Fig. 12E, neuron “c”). Fig. 12F shows that in 
untreated Ts65Dn mice, DCX-positive cells of each category had fewer processes than in their 
euploid counterparts. For instance, while in euploid mice most neurons of category “a” had 
branches of order 2 or 3, in untreated Ts65Dn mice there were numerous cells of category “a” with 
only a single process. Observation of the neurons reported in Fig. 12A–H shows that treatment with 
fluoxetine increased the number of branches in neurons of each category both in euploid (Fig. 
12C,G) and Ts65Dn (Fig. 12D,H) mice. 
We examined the total dendritic length, total number of segments and mean segment length. The 
latter was obtained by dividing the total dendritic length by the total number of branches. We found 
that Ts65Dn mice had a shorter dendritic length (-32%; Fig. 12I) and a reduced number of segments 
(-48%; Fig. 12J) than euploid mice. In contrast, the mean segment length was greater in Ts65Dn 
than in euploid mice (+33%; Fig. 12K). In euploid mice, treatment with fluoxetine slightly 
increased the total dendritic length (+20%), with no change in segment size and with a marginally 
significant increase in the number of segments (Fig. 12I–K). Importantly, in treated Ts65Dn mice 
the dendritic length (Fig. 12I) and the number of segments (Fig. 12J) underwent a notable increase 
(+85% and +152% respectively), while the mean segment length underwent a reduction (-28%; Fig. 
12K). A comparison between untreated euploid mice and Ts65Dn mice treated with fluoxetine 
showed that trisomic mice had more segments (although this effect was only marginally significant) 
(Fig. 12J) and a greater total dendritic length (+30%; Fig. 12I), indicating that not only was 
dendritic size restored by treatment but it became even greater than that of euploid mice. 
To dissect the effects of trisomy and treatment on details of the dendritic architecture, we examined 
each dendritic order separately. Newborn granule cells of Ts65Dn mice had no high-order dendritic 
branches and, while in euploid mice DCX-positive cells had up to eight orders of branches, in 
Ts65Dn mice they had no branches of orders 7 and 8 (Fig. 13A–C arrows).  
 
 
 
67 
 
 
Figure 12 - Effect of ﬂuoxetine on the dendritic size of newborn granule cells. A–D. Photomicrographs of doublecortin 
(DCX) immunopositive granule cells in an animal from each of the following experimental groups: euploid (A), 
Ts65Dn (B), treated euploid (C) and treated Ts65Dn (D). E–H. Three examples (a–c) of the reconstructed dendritic tree 
of granule cells from animals of each of the following experimental groups: euploid (E), Ts65Dn (F), treated euploid 
(G) and treated Ts65Dn (H). Numbers indicate the different dendritic orders. Calibration in A–H: 20 m. I–L. Mean 
total dendritic length (I), mean number of dendritic segments (J) and mean segment length (K) in untreated euploid and 
Ts65Dn mice, and euploid and Ts65Dn mice treated with ﬂuoxetine. Values in I–K represent mean  standard 
deviation (SD). (*) P < 0.06; *P < 0.05; **P < 0.01; ***P < 0.001 (Duncan’s test after ANOVA). 
 
Analysis of branch length of the individual orders showed that branches of order 1 were notably 
longer (+86%) in untreated Ts65Dn compared with untreated euploid mice, and that the remaining 
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orders of Ts65Dn mice had branches with a similar length as those of euploid mice, except for order 
6 branches, which were shorter (-80%; Fig. 13A). 
Analysis of branch number showed that untreated Ts65Dn mice had a similar number of branches 
of orders 1 and 2 as untreated euploid mice, but fewer branches of orders 3–6 and no branches of 
orders 7 and 8 (Fig. 13B). In Ts65Dn mice, there was a progressive worsening in branch number 
reduction from order 3 to 6 (order 3: -49%, order 4: -66%, order 5: -76%, order 6: -99%). We 
evaluated the total dendritic surface offered by each order by multiplying the number of branches 
(Fig. 13B) by the mean branch length (Fig. 13A) of individual orders. In untreated Ts65Dn mice, 
the dendritic length of order 1 was greater (+86%) than in the euploid counterparts (Fig. 13C). This 
is in agreement with the greater length of branch 1. Consistently with the reduced number of 
branches of orders 3–6, in Ts65Dn mice the dendritic length of orders 3, 4, 5 and 6 was smaller (-
52%, -62%, -78% and -99% respectively) than that of euploid mice (Fig. 13C). 
A comparison between untreated and treated Ts65Dn mice showed that mice treated with fluoxetine 
underwent a reduction in the length of branches of orders 1, 2 and 4 (-39%, -19% and -17% 
respectively) which became similar to those of untreated euploid mice and an increase (+260%) in 
the length of branches of order 6 (Fig. 13A). Importantly, treated Ts65Dn mice acquired branches 
of orders 7 and 8 (Fig. 13B) and the length of these branches was similar to that of untreated 
euploid mice (Fig. 13A). In parallel with these effects, in treated Ts65Dn mice there was an 
increase in the number of branches of orders 2–6 (Fig. 13B). The number of branches became 
similar to (branches of orders 2, 3, 6–8) or even larger than (branches of orders 4 and 5) the number 
of branches seen in untreated euploid mice (Fig. 13B). In agreement with these effects, the length of 
individual orders of treated Ts65Dn mice became similar to or even larger (order 5) than that of 
untreated euploid mice (Fig. 13C). 
A comparison between untreated and treated euploid mice showed that euploid mice treated with 
fluoxetine underwent a small (-18%) reduction in the length of branches of order 2 (Fig. 13A). They 
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also showed an increase in the number of branches of orders 3, 4 and 5 (+19%, +59% and +100% 
respectively; Fig. 13B) and in the total length of orders 4 and 5 (+46% and +100% respectively; 
Fig. 13C) vs. untreated euploid mice. 
 
Figure 13 - Effect of ﬂuoxetine on the dendritic architecture of newborn granule cells. A–C. Quantiﬁcation of the 
mean length (A) and mean number (B) of branches of the different orders and total length of each order (C) in untreated 
euploid and Ts65Dn mice, and euploid and Ts65Dn mice  treated  with  ﬂuoxetine. The arrows indicate the absence of 
branches in untreated Ts65Dn mice. Values in A–C represent mean  standard deviation (SD). *P < 0.05; **P < 0.01; 
***P < 0.001 (Duncan’s test after ANOVA). 
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Taken together, these data indicate that in Ts65Dn mice the dendritic tree of the granule cells is 
hypotrophic starting from the early phases of maturation of newborn cells, and that this effect is 
mainly due to a reduction in the number of branches of intermediate order and a lack of branches of 
higher order. Treatment with fluoxetine rescued total dendritic length by restoring the number of 
branches of intermediate order and inducing the appearance de novo of higher-order branches. Not 
only did fluoxetine fully restore this defect but made the total dendritic length larger than that of 
untreated euploid mice. 
The overall effects of genotype and treatment on the dendritic architecture of the newborn granule 
cells are summarized in the dendrograms of Fig. 14. 
 
 
Figure 14 - Dendrograms of the newborn granule cells. The dendrograms were obtained from the mean length and 
mean number of branches of each order reported in Figure 12. The number of branches was approximated to the nearest 
integer value (thick lines). Thin lines have been used to indicate a number of branches ranging from 0.1 to 0.5. 
 
4.2 Effect of fluoxetine on the dendritic tree of the oldest granule cell in euploid and Ts65Dn 
mice 
 
Dendritic maturation of the granule cells lasts approximately 50–60 days ((156); (215)). As we were 
interested in establishing the effect of fluoxetine on granule cells that underwent dendritic 
maturation during treatment (P3–P15) and accomplished it in the following 30 days (by P45), we 
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examined Golgi-stained granule neurons located in the outer portion of the granule cell layer (Fig. 
10). We chose mature-looking neurons to make sure that those which were oldest were sampled. 
Fig. 15A–H shows examples of granule cells in the four experimental groups.  
 
Figure 15 - Effect of ﬂuoxetine on the dendritic size of the oldest granule cells. A–D. Photomicrographs of Golgi-
stained granule cells in an animal from each of the following experimental groups: euploid (A), Ts65Dn (B), treated 
euploid (C) and treatedTs65Dn (D). E–H. Two examples (a and b) of reconstructed dendritic tree of granule cells from 
animals of each of the following experimental groups: euploid (E), Ts65Dn (F), treated euploid (G) and treated Ts65Dn 
(H). Numbers indicate the different dendritic orders. Calibration in A–H: 40 mm. I–K. mean total dendritic length (J), 
mean number of dendritic segments (J) and mean segment length (K) in untreated euploid and Ts65Dn mice, and 
euploid and Ts65Dn mice treated with ﬂuoxetine. Values in I–K represent mean ±standard deviation (SD). *P < 0.05; 
**P < 0.01; ***P < 0.001 (Duncan’s test after ANOVA). 
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It can be noted that in Ts65Dn mice (Fig. 14B,F) the dendritic tree of the granule cells was less 
developed than in euploid mice (Fig. 15A,E). After treatment with fluoxetine, the dendritic pattern 
of Ts65Dn mice (Fig. 15D,H) became similar to that of untreated euploid mice. 
Quantification of the dendritic size showed that Ts65Dn mice had a shorter dendritic length (-36%; 
Fig. 15I) and a reduced number of segments (-45%; Fig. 15J) than euploid mice. In contrast, the 
mean segment length was larger than in euploid mice (+17%; Fig. 15K). While in euploid mice 
treatment with fluoxetine had no effect on dendritic length, number of segments and segment size 
(Fig. 15J,K), in treated Ts65Dn mice the dendritic length (Fig. 15I) and the number of segments 
(Fig. 15J) underwent an increase and the mean segment length underwent a reduction (Fig. 15K). 
All these parameters became similar to those of untreated euploid mice. 
The analysis of each dendritic order showed the absence of branches of higher order in Ts65Dn 
mice. While euploid mice had up to nine orders of branches, Ts65Dn mice completely lacked 
branches of orders 7–9 (Fig. 16A–C arrows). Analysis of the branch length of individual orders 
showed no effects of either genotype or treatment on branches of orders 4–6. In contrast, branches 
of orders 1–3 were notably longer in untreated Ts65Dn vs. untreated euploid mice (Fig. 16A). 
Analysis of the number of branches showed that untreated Ts65Dn mice had a similar number of 
branches of orders 1 and 2 as untreated euploid mice, fewer branches of orders 3–6 and, as noted 
above, no branches of order higher than 6 (see arrows in Fig. 16B). In Ts65Dn mice, there was a 
progressive worsening in branch number reduction from order 3 to 6 (order 3: -13%, order 4: -56%, 
order 5: -70%, order 6: -91%). We evaluated the total dendritic surface offered by each order by 
multiplying the number of branches (Fig. 16B) by the mean branch length (Fig. 16A) of individual 
orders. Evaluation of the total dendritic surface offered by each order showed that in untreated 
Ts65Dn mice, the total length of orders 1, 2 and 3 was larger (+93%, +46% and +26% respectively) 
compared with the euploid counterparts (Fig. 16C).  
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Figure 16 - Effect of ﬂuoxetine on dendritic architecture of the oldest granule cells. A–C. Quantiﬁcation of the 
mean length (A) and mean number (B) of branches of the different orders and total length of each order (C) in untreated 
euploid and Ts65Dn mice, and euploid and Ts65Dn mice treated with  ﬂuoxetine. The arrows indicate the absence of 
branches in untreated Ts65Dn mice. Values in A–C represent mean  standard deviation (SD). *P < 0.05; **P < 0.01; 
***P < 0.001 (Duncan’s test after ANOVA). 
 
 
This is in agreement with the greater branch length of these orders in Ts65Dn mice. In agreement 
with the reduced number of branches of orders 4–6, in Ts65Dn mice the total length of orders 4, 5 
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and 6 was reduced (-60%, -75% and -8% respectively) compared with that of euploid mice (Fig. 
16C). 
A comparison between untreated and treated Ts65Dn mice showed that mice treated with fluoxetine 
underwent a reduction in the length of branches of orders 1–3 (Fig. 16A) and an increase in the 
number of branches of orders 3–6, thus showing a pattern that became similar to that of untreated 
euploid mice. Importantly, treated Ts65Dn mice acquired branches of orders 6–8 and the number 
and length of these branches were similar to that of untreated euploid mice (Fig. 16A,B). In 
agreement with these effects, the length of individual orders of treated Ts65Dn mice became similar 
to that of untreated euploid mice (Fig. 16C). 
A comparison between untreated and treated euploid mice showed that euploid mice treated with 
fluoxetine had fewer branches of orders 5 and 6 (-40% and -53% respectively; Fig. 16B), with no 
change in the mean branch length (Fig. 16A). In agreement with these effects, in treated euploid 
mice the total length of orders 5 and 6 was reduced (-40% and -62% respectively) compared with 
that of untreated euploid mice (Fig. 16C). 
 
 
Figure 17 - Dendrograms of the oldest granule cells. The dendrograms were obtained from the mean length and mean 
number of branches of each order reported in Figure 15. The number of branches was approximated to the nearest 
integer value (thick lines). Thin lines have been used to indicate a number of branches ranging from 0.1 to 0.5. 
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Taken together, these results indicate a severe hypotrophy of the dendritic tree of the granule cells 
of Ts65Dn mice that is mainly due to a notably reduced number of branches of intermediate order 
and total lack of branches of higher order. Treatment with fluoxetine rescued total dendritic length 
by restoring the number of intermediate order branches and inducing the appearance de novo of 
higher order branches. 
The overall effects of genotype and treatment on the dendritic architecture of the mature granule 
neurons are summarized in the dendrograms of Fig. 17. 
 
Figure 18 - Effect of ﬂuoxetine on spine density in the oldest granule cells. A–D. Photomicrograph of Golgi-stained 
granule cells showing distal dendritic branches in an animal from each of the following experimental groups: euploid 
(A), Ts65Dn (B), treated euploid (C) and treated Ts65Dn (D). Calibration: 10 m. E,F. Spine density in the proximal 
(E) and distal (F) dendritic branches of untreated euploid and Ts65Dn mice, and euploid and Ts65Dn mice treated with 
ﬂuoxetine. Values represent mean ± standard deviation (SD). *P < 0.05; **P < 0.01; ***P < 0.001 (Duncan’s test after 
ANOVA). 
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4.3 Effect of fluoxetine on granule cell spine density in euploid and Ts65Dn mice 
 
Neurons receive their excitatory inputs through dendritic spines. Evidence in two mouse models of 
DS shows a spine density reduction along the dendritic tree of the granule cells ((23); (22)). To 
establish whether fluoxetine rescues this defect, we examined spine density in untreated and treated 
mice. Figure A–D shows that in untreated Ts65Dn mice the dendrites of the granule cells had fewer 
spines (Fig. 18B) compared with euploid mice (Fig. 18A) and that treatment increased spine 
number (Fig. 18 7D).  
Quantification of spine density showed that in untreated Ts65Dn mice, spine density was notably 
lower than that of untreated euploid mice, both at the level of the inner (-43%; Fig. 18E) and outer 
(-35%; Fig. 18F) portions of the molecular layer. After treatment with fluoxetine, Ts65Dn mice 
underwent a notable increase in spine density that became similar to that of untreated euploid mice 
in the inner half of the molecular layer (Fig. 18E), and became even larger in comparison with 
euploid mice in the outer half (Fig. 18F). In treated euploid mice, spine density increased compared 
with that of untreated mice, both in the inner half (+44%; Fig. 18E) and outer half (+22%; Fig. 18F) 
of the molecular layer. 
 
4.4 Effect of fluoxetine on hippocampal SYN levels in euploid and Ts65Dn mice 
 
It is likely that a reduction in connectivity is the counterpart of the severe dendritic hypotrophy that 
characterizes the granule cells of Ts65D mice. SYN (also known as p38) is a synaptic vesicle 
glycoprotein that is a specific marker of presynaptic terminals. 
Evaluation of SYN levels in the hippocampal formation (DG plus hippocampus proper) by Western 
blot analysis showed that Ts65Dn mice had reduced SYN levels and that treatment restored SYN 
levels (Fig. 19A,B). SYN levels also increased in treated euploid mice and became higher than in 
untreated euploid mice (Fig. 19A,B). Next, we examined SYN IR in order to obtain specific 
information on SYN levels in the molecular layer of the DG. Fig. 19C shows representative images 
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from animals of each group. It can be readily appreciated that IR for SYN was reduced in Ts65Dn 
mice compared with untreated euploid mice and that it was increased by treatment with fluoxetine. 
Quantitative analysis showed that in untreated Ts65Dn mice, the optical density (OD) of SYN was 
significantly lower than in untreated euploid mice in the middle (-35%) and outer (-48%) molecular 
layers. A marginally significant reduction was present also in the inner molecular layer (Fig. 19D). 
In Ts65Dn mice treated with fluoxetine, the OD of SYN underwent a large increase in all zones of 
the molecular layer and became even greater than that found in untreated euploid mice (Fig. 19D). 
An increase in the OD of SYN also took place in treated euploid mice in all zones of the molecular 
layer (Fig. 19D). 
 
Figure 19 - Effect of ﬂuoxetine on connectivity in the molecular layer. A,B. Western blot analysis of synaptophysin 
levels in the hippocampal formation of untreated and treated mice. Western immunoblots in (A) are examples from 
animals of each experimental group. Histograms in (B) show synaptophysin levels normalized to glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and expressed as fold difference in comparison to untreated euploid mice. C. 
Images of sections processed for synaptophysin immunoﬂuorescence from the dentate gyrus (DG) of an animal from 
each experimental group. Calibration: 50 µm. D. Optical density of synaptophysin immunoreactivity in the inner, 
middle and outer third of the molecular layer of untreated and treated euploid and Ts65Dn mice. Data are given as fold 
difference vs. inner molecular layer of untreated euploid mice. Values in B, D represent mean ± standard deviation 
(SD). (*) P < 0.06; *P < 0.05; **P < 0.01; ***P < 0.001 (Duncan’s test after ANOVA). 
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4.5 Effect of fluoxetine on the glutamatergic innervation of the granule cells in euploid and 
Ts65Dn mice 
 
Perforant path fibers, which take their origin from the entorhinal cortex and use glutamate as a 
neurotransmitter, innervate the middle and outer third of the molecular layer (10). In view of the 
key role of this input in hippocampus-dependent memory functions, we examined the effects of 
trisomy and treatment on glutamatergic terminals in the DG. To this purpose, we evaluated the co-
localization of SYN and the VGLUT1 in the outer and middle third of the molecular layer.  
 
Figure 20 - Effect of ﬂuoxetine on the glutamatergic input in the molecular layer. A–H. Images of sections 
processed for double-labeling immunoﬂuorescence with an anti-synaptophysin antibody (green) and an anti-vesicular 
glutamate transporter 1 (VGLUT1) antibody (red) from the outer molecular layer of the DG of an animal from each of 
the following experimental groups: euploid (A,B), Ts65Dn (C,D), treated euploid (E,F) and treated Ts65Dn (G,H). 
Images in B, D, F, H represent co-localization (white) between synaptophysin (SYN) and VGLUT1. Calibration: 5 µm 
(applies to A–H). M. Coefﬁcient of co-localization of SYN and VGLUT1 in the inner, middle and outer third of the 
molecular layer of untreated and treated euploid and Ts65Dn mice. Values in I represent mean ± standard deviation 
(SD). (*) P < 0.06; *P < 0.05; **P < 0.01; ***P < 0.001 (Duncan’s test after ANOVA). 
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Figure 21 - Effect of ﬂuoxetine on Down syndrome cell adhesion molecule (DSCAM) immunoreactivity in the 
dentate gyrus. A,B. Western blot analysis of DSCAM levels in the hippocampal formation of untreated and treated 
mice. Western immunoblots in (A) are examples from animals of each experimental group. Histograms in (B) show 
DSCAM levels normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and expressed as fold difference 
in comparison to untreated euploid mice. C–F. Images of sections processed for DSCAM immunoreactivity from the 
dentate gyrus (DG) of an animal from each of the following experimental groups: euploid (C), Ts65Dn (D), treated 
euploid (E) and treated Ts65Dn (F). Calibration: 50 mm (applies to C–F). G. Optical density of DSCAM 
immunoreactivity in the molecular layer of untreated and treated euploid and Ts65Dn mice. Data are given as fold 
difference vs. untreated euploid mice. Values in B, G represent mean ± standard deviation (SD). *P < 0.05; **P < 0.01; 
***P < 0.001 (Duncan’s test after ANOVA). 
 
We additionally examined the inner third, which mainly contains glutamatergic terminals of the 
mossy cells (10).We found that co-localization of SYN and VGLUT1 was reduced in untreated 
Ts65Dn as compared with euploid mice in the inner, middle and outer third of the molecular layer 
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(Fig. 19A–I), indicating a generalized reduction of excitatory afferents. Importantly, in treated 
Ts65Dn mice, co-localization of SYN and VGLUT1 increased in all zones of the molecular layer 
and became similar to that of untreated euploid mice (Fig. 20A–I), suggesting restoration of the 
glutamatergic inputs. In euploid mice, treatment had no effect on co-localization of SYN and 
VGLUT1. 
 
4.6 Effect of fluoxetine on DSCAM levels in the DG of euploid and Ts65Dn mice 
 
The mechanisms underlying dendritic pathology in DS have not been elucidated and there is no 
clear evidence as to the role played by triplicated genes in the DS aberrant dendritic phenotype. 
DSCAM is a triplicated gene of HSA21.  
Over-expression in hippocampal neurons of DSCAM dramatically inhibits dendritic branching, 
strongly suggesting that DSCAM over-expression may be a determinant of the dendritic pathology 
in DS (9). DSCAM mRNA has been shown to be localized to dendrites where it is translated (9). 
Dendritic levels of DSCAM protein are regulated by synaptic activity at the NMDA receptor 
(NMDAR). In particular, activation of this receptor increases DSCAM levels. Evaluation of 
DSCAM levels in the hippocampal formation (hippocampus plus DG) by Western blot analysis 
showed that Ts65Dn mice had higher DSCAM levels than untreated euploid mice (Fig. 21A,B). 
After treatment with fluoxetine, Ts65Dn mice underwent a reduction in DSCAM levels that became 
similar to those of untreated euploid mice (Fig. 21A,B). In sections immunostained for DSCAM, 
we quantified DSCAM IR in the DG. We found that the OD of DSCAM in untreated Ts65Dn mice, 
similarly to Ts1Cej mice (9), was higher than euploid mice (Fig. 21C–G). In the DG of Ts65Dn 
mice treated with fluoxetine, the OD of DSCAM became similar to that of untreated euploid mice 
(Fig. 21C–G), suggesting that this reduction may underlie the recovery of granule cell dendritic 
architecture. 
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4.7 Effect of fluoxetine on the hippocampal serotonergic system in euploid and Ts65Dn mice 
 
A profuse network of serotonin (5-HT) containing axons originating from the dorsal and medial 
raphe nuclei innervates the hippocampus and DG (16). In a previous study, we found that Ts65Dn 
mice aged 15 days had no differences in serotonin levels but reduced levels of the 5-HT1A receptor 
((28)). 
Quantification of 5-HT by HPLC in the hippocampal region (hippocampus plus DG) of treated and 
untreated P45 mice showed that Ts65Dn mice had a lower 5-HT concentration (Fig. 22A), and a 
lower concentration of the 5-HT metabolite 5-HIAA (Fig. 21B) than euploid mice. However, there 
was a similar expression of the serotonin transporter (SERT) (Fig. 22C). After treatment with 
fluoxetine, the levels of 5-HT and 5-HIAA underwent an increase and became similar to those of 
euploid mice (Fig. 22A,B), with no changes in the expression of SERT (Fig. 22C). Taken together 
these data suggest impairment of the serotonergic input to the hippocampal formation in Ts65Dn 
mice that can be restored by treatment. This is in agreement with the overall connectivity increase 
found in the DG of treated trisomic mice (Fig. 19A–D). 
At P45, unlike P15 (28), the hippocampal expression of the 5-HT1A receptor was similar in 
Ts65Dn and euploid mice (Fig. 22D). After treatment with fluoxetine, both Ts65Dn and euploid 
mice exhibited a reduction in the expression of the 5-HT1A receptor compared with their untreated 
counterparts (Fig. 22D). This may represent a compensatory mechanism caused by the increased 
bioavailability of serotonin induced by treatment. In view of the role of the 5-HT1A receptor in 
neurogenesis and dendritic development ((33); (64); (210)), we compared its expression in euploid 
and Ts65Dn mice at three different ages. We found that both in euploid and Ts65Dn mice the 
expression of the 5-HT1A receptor increased with age (Fig. 22E). Importantly, its expression was 
lower in Ts65Dn mice compared with the euploid counterparts at P2 and P15, but not at P45. This 
indicates failure of the 5-HT1A receptor in a period (P2–P15) that is critical for two fundamental 
processes: neurogenesis and dendritogenesis. 
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Figure 22 – Effect of ﬂuoxetine on serotonin levels and serotonin receptor expression in the hippocampal 
formation. A,B. Levels of serotonin (5-HT) (A) and of the serotonin metabolite hydroxy indolic acid (5-HIAA) (B) 
measured with high-performance liquid chromatography (HPLC) in the hippocampal formation of P45 untreated 
euploid and Ts65Dn mice and P45 euploid and Ts65Dn mice treated with ﬂuoxetine. Values represent mean ± standard 
deviation (SD). C–E. RNA expression levels quantiﬁed by real-time quantitative PCR (RT-qPCR) of the serotonin 
transporter (SERT) (C), 5-HT1A receptor (D) in the hippocampal formation of P45 untreated and treated euploid and 
Ts65Dn mice, and in the hippocampal formation of untreated euploid and Ts65Dn mice at P2, P15 and P45 (E). Data 
are expressed as fold difference in comparison with untreated P45 euploid mice (C, D) or compared with P2 euploid 
mice (E). Data of P45 mice in E are the same as those in D. Values represent the mean ± standard deviation (SD). *P < 
0.05; **P < 0.01. (Duncan’s test after ANOVA). 
 
 
4.8 Effect of fluoxetine on spine density on the proximal shaft of CA3 pyramidal neurons in 
euploid and Ts65Dn mice 
 
The mossy fiber axons establish multiple asymmetrical synapses with the thorny excrescences on 
the proximal portion of the apical dendritic tree of CA3 pyramidal neurons. Recent evidence shows 
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a decreased number of thorns on the thorny excrescences of Ts65Dn mice aged six months (142). 
We were interested in establishing whether a reduction in the density of spines forming the thorny 
excrescences is already present in mice aged 45 days and whether fluoxetine rescues this defect. 
Images in Fig. 23A show that in untreated Ts65Dn mice there were patently fewer spines compared 
to euploid mice and that treatment increased their number. An increase in spine density also took 
place in treated euploid mice (Fig. 23A).  
 
Figure 23 - Effect of fluoxetine on CA3 pyramidal neuron spine density. A: Photomicrograph of Golgi-stained field 
CA3 pyramidal cells showing the spinous excrescences on the proximal apical dendritic shaft in an animal from each 
experimental group. Scale bar = 10 µm. B: Density of spines on the proximal apical dendritic shaft in the stratum 
lucidum of field CA3 of untreated euploid, untreated Ts65Dn, treated euploid and treated Ts65Dn mice. Spine density 
is expressed as number of spines per 20 µm of dendrite. Values represent mean ± standard deviation (SD). * P < 0.05; 
** P < 0.01; *** P < 0.001 (Duncan’s test after ANOVA). 
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Quantification of spine density showed that in untreated Ts65Dn mice spine density was notably 
lower (-40%) than that of untreated euploid mice (Fig. 23B). After treatment with fluoxetine, 
Ts65Dn mice underwent an increase in spine density that became similar to that of untreated 
euploid mice (Fig. 23B).  
 
Figure 24 - Effect of fluoxetine on the thickness of the mossy fiber terminal field. A–D: Examples of coronal 
sections, processed for PSA-NCAM immunohistochemistry, across the hippocampal formation of an animal from each 
of the following experimental groups: euploid (A), Ts65Dn (B), treated euploid (C), and treated Ts65Dn (D). Sections 
were taken at approximately the same distance from the rostral border of the hippocampal formation. The mossy fiber 
system (indicated by arrows) can be clearly recognized for its dark color and its abrupt termination at the border 
between CA3 and CA2. The scale bar = 300 µm applies to A–D. Abbreviations: DG, dentate gyrus; MF, mossy fibers. 
C: Mean thickness of the mossy fiber terminal field in CA3 in untreated euploid, untreated Ts65Dn, treated euploid and 
treated Ts65Dn mice. The mean thickness was obtained by dividing the area occupied by the mossy fibers by the length 
of CA3. Values represent mean ± standard deviation (SD). * P < 0.05; ** P< 0.01 (Duncan’s test after ANOVA). 
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Treatment also induced a significant increase in spine density in euploid mice (+30% compared to 
untreated mice). 
 
4.9 Effect of fluoxetine on the size of the mossy fiber bundle in euploid and Ts65Dn mice 
 
The granule cells send their axons, the mossy fibers, to field CA3. The region of synaptic contact 
forms a layer called the stratum lucidum (Fig. 9A). The mossy fiber axons express PSA-NCAM 
((171); (165)), which makes it possible to examine this bundle in sections immunoprocessed for 
PSA-NCAM. Ts65Dn mice have a reduced number of granule cells in comparison with euploid 
mice ((28)), which implies a reduction in the number of mossy fibers reaching the stratum lucidum. 
A reduced number of fibers may result in a reduced thickness of the terminal field of the mossy 
fibers in field CA3. To obtain information regarding this issue we examined the size of the mossy 
fiber system in the stratum lucidum of field CA3. Fig. 24A,B shows that the mossy fiber system 
was patently less prominent in Ts65Dn than in euploid mice. 
Quantification of the mean thickness of the mossy fiber bundle within CA3 showed that in Ts65Dn 
mice it was smaller (-13%) than in euploid mice (Fig. 24E). In euploid mice, treatment with 
fluoxetine did not change the mean thickness of the mossy fiber bundle (Fig. 24A–E). Importantly, 
in trisomic mice treated with fluoxetine the thickness of the mossy fiber bundle increased and 
became similar to that of untreated euploid mice (Fig. 24A–E). 
 
4.10 Effect of fluoxetine on overall innervation in the stratum lucidum of euploid and Ts65Dn 
mice 
 
In order to obtain information on overall connectivity to the stratum lucidum, we examined the 
immunoreactivity for SYN in this layer. Fig. 25A shows representative images from animals of 
each group. It can be readily appreciated that the immunoreactivity for SYN was reduced in 
Ts65Dn mice compared to untreated euploid mice and that treatment with fluoxetine increased SYN 
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immunoreactivity both in Ts65Dn and euploid mice. Quantitative analysis showed that in untreated 
Ts65Dn mice the optical density (OD) of SYN was significantly lower (-20%) than in untreated 
euploid mice. In Ts65Dn mice treated with fluoxetine, the OD of SYN underwent a large increase 
and became similar to that found in untreated euploid mice (Fig. 25B). An increase in the OD of 
SYN also took place in treated euploid mice with an increase of 60% in comparison with untreated 
euploid mice (Fig. 25B). 
 
Figure 25 - Effect of fluoxetine on overall innervation in stratum lucidum of field CA3. A: Images of sections 
processed for synaptophysin immunofluorescence from field CA3 from an animal of each experimental group. Scale 
bar = 50 µm. B: Optical density of synaptophysin immunoreactivity in the stratum lucidum of untreated euploid, 
untreated Ts65Dn, treated euploid and treated Ts65Dn mice. Data are given as fold difference vs. the stratum lucidum 
of untreated euploid mice. C: Images, taken with the confocal microscope, of sections processed for synaptophysin 
immunofluorescence from the stratum lucidum of field CA3 from an animal of each experimental group. Scale bar = 5 
µm. D: Number of puncta per µm2 exhibiting synaptophysin immunoreactivity in untreated euploid, untreated Ts65Dn, 
treated euploid and treated Ts65Dn mice. Values in B and D represent mean ± standard deviation (SD). ** P < 0.01; 
*** P < 0.001 (Duncan’s test after ANOVA). 
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Differences in SYN immunoreactivity among groups may be attributable to differences in the 
number of synaptic terminals and/or to differences in the number of synaptic vesicles contained in 
each terminal. To establish possible differences among groups in the overall number of synaptic 
contacts, we evaluated the density of individual puncta exhibiting SYN immunoreactivity in the 
stratum lucidum. Fig. 25C shows representative images from animals of each experimental group. 
We found that untreated Ts65Dn mice had fewer puncta (-31%) exhibiting SYN immunoreactivity 
than the euploid counterparts (Fig. 25D), suggesting that fewer synapses overall are established on 
CA3 pyramidal neurons. Treatment with fluoxetine increased the density of SYN puncta both in 
Ts65Dn and euploid mice (Fig. 25D).  
 
Figure 26 – Effect of fluoxetine on hippocampal VGLUT1 levels. A–B: Western blot analysis of VGLUT1 levels in 
the hippocampal formation of untreated euploid, untreated Ts65Dn, treated euploid and treated Ts65Dn mice. Western 
immunoblots in (A) are examples from an animal of each experimental group. Histograms in (B) show VGLUT1 levels 
normalized to GAPDH and expressed as fold difference in comparison with untreated euploid mice. C: Images of 
sections processed for VGLUT1 immunofluorescence from field CA3 of an animal of each experimental group. Scale 
bar = 50 µm. D: Optical density of VGLUT1 immunoreactivity in the stratum lucidum of untreated euploid, untreated 
Ts65Dn, treated euploid and treated Ts65Dn mice. Number of analyzed sections: 3–4 per animal. Data are given as fold 
difference vs. stratum lucidum of untreated euploid mice. Values in B and D represent mean ± standard deviation (SD). 
** P < 0.01; *** P < 0.001 (Duncan’s test after ANOVA). 
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A comparison between treated and untreated euploid mice showed that the former had significantly 
more SYN puncta (+38%) than the latter (Fig. 25D), suggesting an increase in the number of 
synaptic terminals also in euploid mice. 
 
4.11 Effect of fluoxetine on glutamatergic innervation in the stratum lucidum of euploid and 
Ts65Dn mice 
 
The granule cells use glutamate as a neurotransmitter. Their axons form large complex ‘‘mossy’’ 
synapses on the thorny excrescences covering the proximal apical dendritic shaft of CA3 pyramidal 
neurons. In addition, the granule cell axons give origin to thin philopodial extensions and small en 
passant boutons onto local circuit inhibitory interneurons primarily located within the stratum 
lucidum ((2); (109)) (Fig. 9B).  
To establish the effect of trisomy and treatment on the glutamatergic input we evaluated the 
glutamate vesicular transporter 1 (VGLUT1) levels in the hippocampal formation (dentate gyrus 
plus hippocampus proper) using Western blot analysis. Results showed that Ts65Dn mice had 
reduced VGLUT1 levels that were restored with treatment (Fig. 26A,B). VGLUT1 levels also 
increased in treated euploid mice and became higher than in untreated euploid mice (Fig. 26A,B). 
To specifically establish the effect of trisomy and treatment on the glutamatergic terminals from the 
DG, we evaluated immunoreactivity for the glutamate vesicular transporter 1 (VGLUT1) in the 
stratum lucidum of treated and untreated mice. Fig. 26C shows representative images from animals 
of each group. It can be noted that the immunoreactivity for VGLUT1 was reduced in Ts65Dn mice 
compared to untreated euploid mice and that treatment with fluoxetine increased VGLUT1 
immunoreactivity both in Ts65Dn and euploid mice. In untreated Ts65Dn mice the OD of VGLUT1 
was significantly lower (-25%) than in untreated euploid mice (Fig. 26D). In Ts65Dn mice treated 
with fluoxetine, the OD of VGLUT1 underwent an increase and became similar to that found in 
untreated euploid mice (Fig. 26D). 
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The OD of VGLUT1 also increased by 66% in treated euploid mice compared with untreated 
euploid mice (Fig. 26D).  
The stratum lucidum harbors, in addition to excitatory projections from the granule cells of the DG, 
inhibitory interneurons that impinge upon the proximal shaft of field CA3 pyramidal neurons ((2), 
(109)). In order to establish the effect of trisomy and treatment on the relative abundance of 
glutamatergic terminals we examined the co-localization of SYN and VGLUT1 in the stratum 
lucidum of treated and untreated mice.  
 
Figure 27 - Effect of fluoxetine on the glutamatergic innervation in stratum lucidum of field CA3. A, B: Images, 
taken with the confocal microscope, of sections processed for double-labeling immunofluorescence with an anti-
synaptophysin antibody (green) and an anti-VGLUT1 antibody (red) from the stratum lucidum of an animal from each 
experimental group. Images in (B) represent colocalization (white) between these two markers. Images correspond to 
the same images shown in Figure 24C. Scale bar = 5 µm. C: Coefficient of colocalization of synaptophysin (SYN) and 
VGLUT1 in stratum lucidum of untreated euploid, untreated Ts65Dn, treated euploid and treated Ts65Dn mice. Values 
in B and D represent mean ± standard deviation (SD). (Duncan’s test after ANOVA). 
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Fig. 25A shows representative images processed for double-labeling immunofluorescence with an 
anti-synaptophysin antibody (green) and an anti-VGLUT1 antibody (red) and Fig. 27B shows the 
colocalization (white) of these markers. We found no differences among groups in the co-
localization of SYN and VGLUT1 (Fig. 26C). The colocalization coefficient had a high value 
(approximately 0.8), which is consistent with the prevalence of glutamatergic projections to the 
stratum lucidum. The similarity in the co-localization coefficient between euploid and Ts65Dn mice 
indicates that, though in trisomic mice there were fewer synaptic terminals, the ratio of 
glutamatergic (excitatory) and non-glutamatergic (inhibitory) synapses was similar to that of 
euploid mice. Likewise, in trisomic and euploid mice treated with fluoxetine, the finding that the 
co-localization coefficient was unchanged in comparison with the untreated counterparts indicates 
that the overall increase in the number of synaptic contacts involved, in a proportional manner, 
excitatory and inhibitory synapses. 
 
4.12 Effect of fluoxetine on basal synaptic input in CA3 neurons 
 
‘‘Miniature’’ synaptic events reflect the spontaneous release of neurotransmitters from all 
presynaptic terminals converging on the recorded neuron. The frequency of these events is related 
to the total number of presynaptic terminals and the probability of release at each terminal. To 
functionally evaluate the basal excitatory and inhibitory synaptic input to CA3 pyramidal neurons, 
we recorded spontaneous miniature excitatory postsynaptic currents (mEPSCs) and miniature 
inhibitory postsynaptic currents (mIPSCs) from individual pyramidal neurons by performing whole-
cell, patch-clamp experiments in the voltage-clamp mode. Miniature events were recorded in the 
presence of tetrodotoxin (TTx, 1 µM) in the perfusing solution, so as to prevent spontaneous 
synaptic events due to presynaptic action-potential firing. In each cell, mEPSC and mIPSC activity 
was continuously recorded for a period of at least 5 min and up to 10 min. 
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Figure 28 - Effect of fluoxetine on mEPSC frequency in CA3 pyramidal neurons. A: Exemplary current tracings 
recorded in the gap-free mode in four representative cells from untreated euploid and Ts65Dn mice and euploid and 
Ts65Dn mice treated with fluoxetine, showing mEPSC activity. B: Average frequency- distribution diagrams of 
mEPSC amplitude for untreated euploid and Ts65Dn mice (B1) and euploid and Ts65Dn mice treated with fluoxetine 
(B2). Numbers of observations are: 8 (euploid, untreated mice), 4 (Ts65Dn, untreated mice), 7 (euploid, fluoxetine-
treated mice), and 5 (Ts65Dn, fluoxetine- treated mice) (these values indicate the number of animals of each group from 
which recordings were obtained; 2 to 4 cells were recorded from each animal). C: Average, overall mEPSC frequency 
in the four animal groups (n: as above). One-way ANOVA revealed the existence of a statistically significant difference 
among groups (P = 0.007). *, P < 0.05 (Bonferroni post-test; the same test also revealed a significant difference, at the 
0.01 level, between Ts65Dn, untreated mice and euploid, fluoxetine-treated mice). 
 
For mEPSC recording, the holding potential was set at -70 mV, a level that, under our experimental 
conditions, was close to the theoretical equilibrium potential of chloride ions (-71.5 mV), and 
therefore to the reversal potential of GABAergic currents: this allowed for mEPSC recording in 
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virtual isolation from mIPSCs. Fig. 28A shows examples of mEPSCs recorded, under the above 
conditions, in representative cells from untreated and fluoxetine-treated euploid and trisomic mice.  
 
Figure 29 - Effects of fluoxetine on mEPSCs due to mossy-fiber input to CA3 pyramidal neurons. A–D: Average 
frequency-distribution diagrams of mEPSC amplitude for untreated euploid (A) and Ts65Dn (B) mice, and fluoxetine-
treated euploid (C) and Ts65Dn (D) mice, before (open symbols) and during (filled symbols) application of the group-II 
metabotropic glutamate receptor (mGluR) agonist, DCG-IV plus APV. The shadowed areas correspond to the 
frequency of the mEPSC activity removed by this drug treatment. Numbers of observations are: 8 (euploid, untreated 
mice), 4 (Ts65Dn, untreated mice), 6 (euploid, fluoxetine-treated mice), and 5 (Ts65Dn, fluoxetine-treated mice). E: 
Average, overall frequency of the mEPSC activity removed by DCG-IV+APV treatment, obtained by subtraction, in the 
four animal groups (n: as above). One-way ANOVA revealed the existence of a statistically significant difference 
among groups (P < 0.001). * and **, p < 0.05 and 0.01, respectively (Bonferroni post-test; the same test also revealed a 
significant difference, at the 0.001 level, between Ts65Dn, untreated mice and euploid, fluoxetine-treated mice). 
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No spontaneous synaptic events were observable any longer after application of the glutamatergic 
inhibitors, NBQX (10 µM)+APV (50 µM) (n=4 cells; not shown). Due to baseline noise levels 
normally observed at -70 mV, events of less than 10 pA in peak amplitude were ignored. Accepted 
events were then used to construct frequency-distribution diagrams of mEPSC amplitude. Data 
were averaged among the cells from each animal (n = 2 to 4), and then among the animals 
pertaining to the same experimental group (untreated euploid or trisomic mice, fluoxetine-treated 
euploid or trisomic mice). The plots thus obtained are shown in Fig. 28B. In untreated mice, the 
trisomic condition was associated with a clear reduction in mEPSC frequency for all amplitude 
classes, with no evident changes in frequency-distribution shape (Fig. 28B1), in accordance with 
previous observations (85). The overall mEPSC frequency was significantly reduced in trisomic 
animals by ∼39% (Fig. 28C). 
The frequency distribution of mEPSC amplitude was also qualitatively similar in fluoxetine-treated 
mice (Fig. 28B2).  
The overall mEPSC frequency was found to be slightly, albeit non significantly, higher in 
fluoxetine-treated euploid mice than in untreated euploid mice. However, in fluoxetine-treated 
trisomic mice it was significantly higher than in untreated trisomic mice and not significantly 
different from the mEPSC frequency found in euploid untreated or treated mice (Fig. 28C). 
The above data show that in trisomic animals fluoxetine treatment increased the basal, excitatory 
synaptic input to pyramidal CA3 neurons to nearly normal levels. The sources of this synaptic input 
include both granule-cell mossy fibers and association afferents from other pyramidal neurons.  
To ascertain whether the synaptic input specifically due to mossy fibers was restored in fluoxetine-
treated trisomic animals, we adopted the same experimental strategy described by Hanson et al. 
(85).  
In a subset of cells of each animal group, after mEPSC recording under basal conditions, the group-
II metabotropic glutamate receptor (mGluR) agonist, DCG-IV (3 µM) was applied in association 
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with the NMDA-receptor antagonist, APV (50 µM). Under these conditions, group-II mGluR 
activation is known to selectively inhibit synaptic transmission in mossy-fiber inputs (85) but not in 
associational connections (97).  
 
Figure 30 - Effects of fluoxetine on mIPSC frequency in CA3 pyramidal neurons. A: Exemplary current tracings 
recorded in the gap-free mode in four representative cells from untreated euploid and Ts65Dn mice and euploid and 
Ts65Dn mice treated with fluoxetine, showing mIPSC activity. 
B: Average frequency-distribution diagrams of mIPSC amplitude for untreated euploid and Ts65Dn mice (B1) and 
euploid and Ts65Dn mice treated with fluoxetine (B2). Numbers of observations are: 8 (euploid, untreated mice), 4 
(Ts65Dn, untreated mice), 7 (euploid, fluoxetine-treated mice), and 5 (Ts65Dn, fluoxetine-treated mice). C: Average, 
overall mIPSC frequency in the four animal groups (n: as above). One-way ANOVA revealed the existence of a 
statistically significant difference among groups (P < 0.01). *, P < 0.05 (Bonferroni post-test; the same test also 
revealed a significant difference, at the 0.05 level, between Ts65Dn, untreated mice and euploid, fluoxetine-treated 
mice). 
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DGC-IV+APV application markedly reduced mEPSC frequency at all amplitude classes in each 
animal group (Fig. 29A-D). The mEPSC activity abolished by DGCIV, quantified by subtracting 
the overall mEPSC frequency in the presence of DCG-IV+APV from the overall mEPSC frequency 
in control conditions, was significantly reduced in untreated trisomic animals as compared to 
euploid animals, but was restored to nearly normal levels in fluoxetine-treated trisomic animals 
(Fig. 29E). These results suggest that fluoxetine treatment was able to recover functionally normal 
synaptic inputs from mossy fibers in CA3 pyramidal neurons. 
mIPSCs were recorded by setting the holding potential at 0 mV, a level close to the reversal 
potential of glutamatergic currents, which allowed for virtual elimination of visible mEPSC activity. 
Examples of mIPSCs recorded in representative cells from the four animal groups considered are 
shown in Fig. 30A. mIPSC activity was abolished by application of the GABAA-ergic inhibitor, 
bicuculline (20 µM) (n =3 cells; not shown). Detected events of >6 pA in peak amplitude were used 
to construct frequency-distribution diagrams of mIPSC amplitude, and data were averaged among 
cells from each animal (n = 2 to 4) and then among animals, as above (Fig. 30B). 
In untreated mice, the trisomic condition was associated with a significant reduction (∼-30%) in 
mIPSC frequency (Fig. 30B1, C), again in accordance with previous observations (85).  
Fluoxetine treatment of trisomic mice restored mIPSC frequency to levels not significantly different 
from those observed in euploid animals (Fig. 30B2, C). 
 
4.13 Effect of fluoxetine on BDNF expression 
 
Neurotrophins and, in particular, the brain-derived neurotrophic factor (BDNF) are important 
regulators of neuronal plasticity. Synaptic reorganization mediated by BDNF is thought to be a 
critical process which shapes neuronal networks. Reduced BDNF expression has been documented 
in the frontal cortex of Ts65Dn mice (29). We previously found that in the hippocampus of Ts65Dn 
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mice aged 15 days BDNF expression was lower than in euploid mice and that BDNF levels were 
restored by treatment with fluoxetine (28).  
 
Figure 31 - Effect of fluoxetine on hippocampal BDNF levels. RNA expression levels of BDNF, quantified by RT-
qPCR, in homogenates of the hippocampal formation from untreated euploid, untreated Ts65Dn, treated euploid and 
treated Ts65Dn mice. Data are given as fold difference in comparison with untreated euploid mice. Values represent 
mean ± standard deviation (SD). * P < 0.05; *** P < 0.001 (Duncan’s  test  after ANOVA). 
 
This suggests that reduced BDNF levels may take part in developmental alterations in the trisomic 
brain and that restoration of BDNF levels may be a determinant of the beneficial effects of 
treatment with fluoxetine. We evaluated here BDNF levels in the hippocampus of mice aged 45 
days. At this age, we found no differences in BDNF levels between untreated euploid and Ts65Dn 
mice (Fig. 31). Normal BDNF levels have been detected in the hippocampus of adult mice, (141) 
suggesting that failure of BDNF production is not a permanent defect in the trisomic hippocampus. 
However, after treatment with fluoxetine in the period P3-P15, Ts65Dn mice and euploid mice aged 
45 days exhibited higher BDNF levels than the untreated counterparts (Fig. 31). This increase was 
approximately +35% in treated vs. untreated euploid mice, and +38% in treated vs. untreated 
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Ts65Dn mice. The increase in BDNF levels in treated mice is consistent with the effects of 
antidepressants on brain BDNF expression (115). 
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5. DISCUSSION 
 
 
The current study provides novel evidence that a brief pharmacological therapy with fluoxetine in 
the early postnatal period fully rescues dendritic pathology and connectivity in the hippocampal DG 
of the Ts65Dn mouse model of DS. This study also shows that in Ts65Dn mice the connectivity 
from the granule cells to field CA3 is impaired and that neonatal treatment with fluoxetine restores 
the anatomy and function of the mossy fiber system, in parallel with total granule cell number.  
In view of the key role of DG and CA3 in declarative memory, these effects are essential for the 
recovery of the trisynaptic network properties and, hence, of hippocampus-dependent memory 
performance. 
In untreated Ts65Dn mice, newborn (DCX-positive) granule cells had abnormally long branches of 
low order and very few branches of higher order (Fig. 14). The dendritic architecture of the 
newborn granule cells of Ts65Dn mice treated with fluoxetine underwent notable changes. In 
particular, total dendritic length notably increased and became even larger than that of untreated 
euploid mice (Figure 12I). This effect was due to a full restoration of the mean branch length and of 
the number of branches of all orders. Importantly, after treatment with fluoxetine both these 
dendritic parameters became similar to those of untreated euploid mice and the absence of high 
order branches was compensated by the de novo appearance of high order branches. Consequently, 
the total length of all individual orders became similar or even larger than that of untreated euploid 
mice (Figure 13). 
The dendritic architecture of the older granule cells of untreated Ts65Dn mice, examined in Golgi-
stained material, closely recapitulated the proximodistal defects of newborn granule cells. (Fig.17). 
This indicates that dendritic hypotrophy starts at the initial stages of granule cell development and is 
retained at later stages. Also in the older granule cells of Ts65Dn mice there was a restoration of the 
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excessive length of low order branches, an increase in the number of branches of intermediate order 
and the de novo appearance of highest order branches after treatment with fluoxetine. Because of 
these readjustments, the total length  of the dendritic tree (Fig. 15I) and its architecture (Fig. 17) 
were fully restored. Moreover, in trisomic mice treated with fluoxetine there was a full restoration 
in spine density both in the inner half (Fig. 18E) and outer half  (Fig. 18F) of the molecular layer of 
DG, which may also notably concur to a more efficient processing of signals. 
In view of the restoration of both dendritic architecture and spine density it is expected that after 
treatment with fluoxetine the superficial granule cells of trisomic mice process entorhinal signal in a 
manner similar to that of the untreated euploid counterpart.  
 
5.1 Fluoxetine rescues connectivity of trisomic granule cells 
 
SYN immunohistochemistry revealed an overall reduction of the inputs to the molecular layer in 
trisomic mice (Fig. 19D). Since synaptogenesis and neuron maturation take place in the first few 
postnatal weeks, treatment with fluoxetine during this critical time window is expected to have a 
significant impact on altered connectivity in the trisomic brain. Consistently with this idea, we 
found that, after treatment with fluoxetine, Ts65Dn mice showed an increase in SYN IR throughout 
the molecular layer. Although it cannot be ruled out that an increase in SYN expression may be due 
to increased levels of the protein contained in individual synapses, the increase in the number of 
dendritic spines in treated trisomic mice is consistent with a treatment-induced increase in the 
overall connectivity of the molecular layer. VGLUT1 immunohistochemistry showed that in 
trisomic mice the glutamatergic input to the molecular layer was reduced, which is consistent with 
the paucity of dendrites and spines of trisomic granule cells. Consistently with restoration of the 
dendritic arbor, treated trisomic mice underwent an increase in the glutamatergic input (Fig. 20I). 
Perforant path fibers convey signals from the entorhinal cortex to the granule cells (10) and the 
hippocampal processing of these signals is essential for long-term declarative memory. Current 
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results suggest that reduction of the glutamatergic input from the entorhinal cortex may be a key 
determinant of memory impairment in trisomic mice. It is likely that recovery of this input 
contributes to the rescue of hippocampus-dependent memory performance previously observed in 
trisomic mice treated with fluoxetine (28). 
 
5.2 Fluoxetine normalizes DSCAM levels in the DG of Ts65Dn mice 
 
The abnormally long low-order dendritic branches and the scanty number of higher-order branches 
in trisomic granule cells suggest that dendritic hypotrophy is due to the failure of the mechanism/s 
that trigger dendritic branching. We found over-expression of DSCAM IR in the DG of trisomic 
mice and that fluoxetine restored DSCAM levels (Fig. 21B,G). This suggests that the dendritic 
hypotrophy of the trisomic brain is underpinned by DSCAM over-expression and that fluoxetine 
rescues this defect by reducing DSCAM levels. 
DSCAM mRNA is translated at dendritic level through an NMDA dependent mechanism. NMDAR 
activation increases dendritic levels of DSCAM protein, while NMDAR inhibition has an opposite 
effect (9). Interestingly, serotonin appears to suppress NMDAR function by activating the 5-HT1A 
receptor (213). This provides a potential mechanism whereby fluoxetine restores dendritic 
development in trisomic mice. The impairment of the serotonergic system in trisomic mice (see 
above) implies a reduced suppression of NMDAR function, which, in turn, may lead to high levels 
of DSCAM protein. Increased serotonin availability, following treatment with fluoxetine, may 
reduce NMDAR function, which, in turn, may reduce DSCAM protein levels, thereby restoring 
dendritic branching. 
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5.3 Restoration of granule cell dendritic development parallels restoration of the serotonergic 
system 
 
The dendritic branching pattern of trisomic DCX-positive cells was rescued by fluoxetine (Fig. 11 
and 12). This indicates a positive impact of treatment on neurons born after the end of treatment. 
The time course of granule cell development (215) implies that the cells we sampled in the outer 
granule cell layer of mice aged 45 days were exposed to treatment during the early period of their 
dendritic maturation. The full dendritic recovery of these cells in treated trisomic mice shows that a 
relatively short period of treatment (13 days) was sufficient to rescue dendritic development, and 
that this effect was retained for up to 1 month after treatment cessation. 
Serotonin is fundamental for granule cell dendritic development through the 5-HT1A receptor, and 
the first 2 postnatal weeks represent a critical time window for serotonin action (210). We 
previously found that in P15 trisomic mice, the serotonergic system was impaired because of 
reduced expression of the 5-HT1A receptor, but with normal levels of serotonin (28). We found 
here that the expression of the 5-HT1A receptor, which was reduced at P2 and P15, recovered by 
P45 (Fig. 22D). In P45 trisomic mice, however, the serotonergic system was impaired because of a 
reduced serotonin level (Fig. 22A). In a study of euploid and Ts65Dn mice by Megias et al (122), 
no differences in the cellularity of the dorsal and medial raphe nuclei (the source of the serotonergic 
input to the forebrain) were detected. In view of the reduced dendritic surface of trisomic granule 
cells, it is likely that the reduced serotonin levels in trisomic mice are the result of a reduction in the 
number of serotonergic terminals. The ﬁnding that in treated trisomic mice serotonin levels became 
similar to those in euploid mice suggests recovery of the serotonergic input (Fig. 22A).  
The reduced expression of the 5HT1A receptor at P2 and P15 (Fig. 22E), a time when most of the 
granule cells are beginning maturation, is likely to aversively affect dendritic growth, in spite of 
normal serotonin levels. The outcome of a reduced dendritic growth is a reduction in the number of 
synaptic contacts established by afferent systems to the granule cells, including the serotonergic 
system. A reduction in the serotonergic input causes, in turn, a reduction in serotonin levels and, 
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hence, further impairs dendritic development. Thus, for different reasons, the serotonergic system 
appears to be altered across critical phases of granule cell formation and maturation. The system 
begins to be deranged because of a low expression of the 5-HT1A receptor. This defect leads to a 
negative process that reinforces itself with time: the fewer the dendrites, the fewer the serotonergic 
synaptic contacts, and so on. 
Treatment with fluoxetine in the P3–P15 period restored the expression of the 5-HT1A receptor in 
P15 trisomic mice (28) and, as found here, restored serotonin levels in P45 mice. By the same line 
of reasoning used above, normalization of the 5-HT1A receptor at P15 may be fundamental in order 
to trigger proper dendritic development during the early phases of granule cell maturation and to 
prevent the entry in the vicious cycle mentioned above. Namely, early normalization of the 
dendritic material may favor the establishment of a proper number of synaptic contacts with 
serotonergic terminals. Correct serotonin levels will further favor dendritic growth and, 
consequently, create a milieu, which is favorable for the dendritic formation of granule cells born 
after treatment cessation. 
 
5.4 Impaired connectivity in the stratum lucidum of field CA3 of Ts65Dn mice 
 
In Ts65Dn mice, consistently with the reduced number of granule cells in the DG (28) and, hence, a 
reduction in mossy fiber axons, the thickness of the mossy fiber bundle in the stratum lucidum of 
CA3 was reduced in comparison with that of euploid mice (Fig. 24E). In agreement with previous 
evidence (106), we found that Ts65Dn mice had overall fewer synaptic terminals and fewer 
glutamatergic terminals in the stratum lucidum (Fig. 25B,D and Fig. 26D) The density reduction of 
the glutamatergic terminals is consistent with the reduced number of granule cells that are the 
source of the glutamatergic input to the stratum lucidum. Since excitatory inputs terminate on 
dendritic spines, the reduced spine density on the thorny excrescences of trisomic mice (Fig. 24B) is 
the counterpart of the reduced density of the glutamatergic terminals. Consistently with the 
 
 
 
103 
 
hypotrophy of the glutamatergic system in the stratum lucidum, in Ts65Dn mice mEPSC frequency 
was notably reduced (Fig. 29E). 
Taken together these data indicate a reduced excitatory drive from the granule cells to the pyramidal 
neurons of CA3 and, consequently, impaired signal processing. The mossy fibers additionally 
innervate inhibitory interneurons in the stratum lucidum that exert a feedforward inhibitory control 
on pyramidal neuron discharge ((2), (109)). If the reduction in the density of the glutamatergic 
terminals in the stratum lucidum of Ts65Dn mice includes synapses on inhibitory interneurons, this 
will result in a reduction in feedforward inhibition, matching the reduction in direct excitation. In 
field CA3 of Ts65Dn mice there was a reduction in the frequency of mIPSCs, which is in line with 
the reduction in the density of non-glutamatergic synapses in the stratum lucidum and suggests a 
reduced inhibitory control on CA3 pyramidal neurons (Fig. 30C). It is important to note that, 
though in absolute terms Ts65Dn mice had fewer excitatory and inhibitory synaptic contacts, the 
ratio of these inputs was similar to that of euploid mice (Fig. 27C) This confirms that in field CA3, 
unlike in the dentate gyrus (103), a shift towards over-inhibition is not present (85). 
 
5.5 Fluoxetine restores the mossy fiber projections and functional connectivity in the stratum 
lucidum of Ts65Dn mice 
 
In agreement with the treatment-induced restoration of total granule cell number (28), the thickness 
of the mossy fiber bundle of treated Ts65Dn mice underwent an increase and became similar to that 
of euploid mice (Fig. 24E). Moreover, after treatment with fluoxetine, Ts65Dn mice showed an 
increase in the overall number of synaptic terminals in the stratum lucidum (Fig. 25B,D). This 
increase was due to a proportionally similar increase in the number of glutamatergic and non 
glutamatergic terminals (Fig. 27C). In parallel, in Ts65Dn mice there was an increase in spine 
density on the proximal shaft of CA3 pyramidal neurons in the stratum lucidum (Fig. 23B). These 
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two effects were accompanied by an increase in the frequency of mEPSC, indicating that the new 
connections were functionally effective (Fig. 28E). 
 
 
Figure 32 - Summary of the effect of fluoxetine on connectivity in  the  stratum  lucidum.  A–D:  Connectivity 
between  the  dentate gyrus (DG) and field CA3 in euploid mice (A), euploid mice treated with fluoxetine (B), Ts65Dn 
mice (C) and Ts65Dn mice treated with fluoxetine (D). Ts65Dn mice have a reduced number of granule cells (GC), 
mossy fibers (MF), glutamatergic terminals (GT) in the stratum lucidum and spines (SP) on the thorny excrescences 
(C). Treatment with fluoxetine rescues all these defects and restores the input from the DG to CA3 (D). The direction of 
the arrows indicates the direction of the defect  and  the effect  of  the  therapy  in comparison  with  untreated euploid 
mice. The double-headed arrows indicate no effect. 
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Importantly, in treated Ts65Dn mice there was also an increase in the frequency of mIPSCs, 
indicating an increase in the inhibitory input to the pyramidal cells (Fig. 30C). In the stratum 
lucidum of field CA3, feedforward inhibition is fundamental for shaping the pattern and duration of 
pyramidal neuron discharge in response to the mossy fiber input (109).  
A reduction in feedforward inhibition would lead to excessive recruitment of pyramidal cells and 
predisposition to epileptiform activity. It appears, thus, of relevance that in treated trisomic mice the 
increase in the number of excitatory synapses was matched by a parallel increase in the inhibitory 
input. The fully recovery of the input from the DG to field CA3 is summarized in Fig. 31. 
 
5.6 BDNF may contribute to synaptic remodeling in field CA3 of Ts65Dn mice treated with 
fluoxetine 
 
BDNF is one of the most potent modulators of synaptic plasticity and spine formation (39);. The 
mossy fiber pathway contains the highest levels of BDNF in the CNS, and BDNF appears to 
regulate both direct excitatory and indirect inhibitory inputs to CA3 pyramidal cells (53). The 
increase in BDNF levels in trisomic mice treated with fluoxetine (Fig. 31) suggests that BDNF may 
concur, in conjunction with the increase in the number of mossy fibers, to favor the formation of 
glutamatergic synapses. BDNF is also present in mossy fiber terminals contacting inhibitory 
neurons (53), suggesting that the increase in the inhibitory innervation in the stratum lucidum of 
treated Ts65Dn mice may also be mediated by mossy fiber BDNF. 
 
5.7 Fluoxetine has moderate or no effects in euploid mice 
 
In euploid mice, fluoxetine caused an increase in SYN levels in the DG similar to trisomic mice 
(Fig. 19D). Treatment, however, had smaller effects on dendritic length and spine density of the 
granule cells than in trisomic mice (Fig. 12I, 15I and Fig. 18E,F). The oldest granule cells of 
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euploid mice even underwent a reduction in the number of some branches. Likewise, no effects of 
fluoxetine were observed on serotonin and DSCAM levels (Fig. 22A and Fig. 21B).  
The thickness of the mossy fiber bundle was not affected by treatment in euploid mice (Fig. 24E), 
which fits with the absence of a significant increase in total granule cell number (28). The large 
increase in synaptophysin immunoreactivity in the stratum lucidum of treated euploid mice (Fig. 
25B) was accompanied by a more moderate increase in the number of synaptophysin 
immunoreactive puncta (Fig. 25D) and the large increase in VGLUT1 immunoreactivity (Fig. 26D) 
was accompanied by a less prominent increase in spine density (Fig. 23B). The similarity in the 
colocalization coefficient of synaptophysin and VGLUT1 between treated and untreated euploid 
mice suggests that, similarly to trisomic mice, treatment increased glutamatergic and 
nonglutamatergic terminals in a proportional manner (Fig. 27C). In treated euploid mice, the 
frequency of mEPSCs and mIPSCs underwent a moderate but not statistically significant increase, 
suggesting that among the surplus of synaptic terminals there were silent terminals (Fig. 29E and 
Fig. 30C). 
It is possible that a relatively short period of treatment, such as the one used here, has large effects 
on brain plasticity under adverse brain conditions but weaker effects in the normal brain. The idea 
that the impact of fluoxetine on normal animals may have relatively scarce advantages, or even 
disadvantages, is strengthened by the observation that in euploid but not in trisomic mice treatment 
with fluoxetine caused a reduction in brain weight and no improvement in hippocampus-dependent 
memory performance (28). 
 
5.8 Conclusions 
 
Neuron generation and dendritic maturation with consequent alteration in connectivity are heavily 
compromised in DS. Thus, therapies to improve brain development should be aimed at restoring all 
these processes. Treatment with fluoxetine in adult Ts65Dn mice has been shown to restore 
 
 
 
107 
 
neurogenesis in the DG (43). No studies have examined the effects of fluoxetine during adulthood 
on dendritic architecture and connectivity. It should be noted that treatments in adulthood are likely 
to moderately impact on brain cellularity and wiring that mainly occur in the very early phases of 
brain development. We previously found that neonatal treatment with fluoxetine fully restores 
hippocampal neurogenesis and memory performance in trisomic mice (28). 
Current results show that treatment with fluoxetine restores dendritic architecture and spine density 
of trisomic granule cells, indicating that the same treatment is able to restore not only the number of 
granule neurons but also their “quality” in terms of correct maturation. Moreover, the rescue of 
dendritic development was accompanied by the rescue of connectivity to the DG . 
 
Figure 33 - Summary of the effects of neonatal treatment with fluoxetine on the hippocampal formation in Ts65Dn 
mice. 
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The fluoxetine-induced rescue of the total number of granule neurons in Ts65Dn mice (28) is an 
essential but not sufficient condition for the functional recovery of the trisynaptic circuit. It is 
equally important that the surplus of granule cells establishes appropriate synaptic contacts with 
CA3, the second element of the trisynaptic circuit. We found here that in trisomic mice treated with 
fluoxetine there was the fully recovery of the input from the DG to field CA3. 
This recovery includes restoration of i) the number of granule cells and, hence, of mossy fibers; ii) 
the density of glutamatergic terminals in the stratum lucidum; and, iii) the density of spines forming 
the thorny excrescences. In addition, electrophysiological evidence showed that the increased 
excitatory connectivity was functionally effective and that the inhibitory input to CA3 was also 
restored. 
Taken together, these data suggest that the restoration of cognitive performance is due not only to 
the rescue of neurogenesis but also to restoration of the organization of the hippocampal circuits. 
The widespread beneficial effects of fluoxetine on the hippocampal formation (Fig. 33) suggest that 
early treatment with fluoxetine can be a suitable therapy, possibly usable in humans, to restore the 
physiology of the hippocampal networks and, hence, memory functions. These findings may open 
the way for future clinical trials in children and adolescents with DS. 
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